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According to the World Health Organization, mental disorders represent the leading 
cause of disability in the US generating ~58 billion dollars in medical costs annually. 
Additionally, among the US population, ~40 million adults suffer from an anxiety disorder and 
~14 million suffer from a major depressive disorder. The association between the persistence of 
these neurobehavioral conditions and central nervous system (CNS) levels of biogenic amines 
and metabolites has been studied for half a century. Further, a number of drugs interfering with 
neurotransmission/metabolism are used clinically for treatment of these disorders. Recently, 
 some members of the solute carrier (SLC) superfamily, the SLC22 transporter family, which 
includes organic anion transporters (Oat1, Oat3), were found to be expressed and functional on 
the apical membrane of the choroid plexus, a component of the blood-cerebrospinal  fluid 
barrier. The cells of this epithelia form tight junctions, which slows penetration of solutes into 
the brain and limits passive efflux of endogenous solutes from the brain. Therefore, Oat1 and 
Oat3 are poised to play an active role in the removal of NTs and metabolites from the CSF. 
Thus, a better understanding of the underlying roles of OATs in regulating CNS 
neurotransmitters and connecting their activity to complex behaviors may result in improved 
understanding of the processes governing CNS homeostasis. 
Basal locomotor, anxiety-like and depressive-like behaviors in mice of three genotypes 
(WT, Oat1-/-, and Oat3-/-) across ages (3-18 mo.) were evaluated using behavioral paradigms 
(e.g. open field activity (OFA), light-dark (LD), marble burying (MB), and tail suspension test 
(TST)). Secondly, a simple high performance liquid chromatography-ultraviolet/electrochemical 
detection (HPLC-UV/ECD) method was developed for quantitation of monoamines and 
metabolites in mouse whole brain. Following completion of behavioral assessments, whole 
brain concentrations of monoamines and metabolites were determined using the developed 
method. Lastly, a novel gas chromatography tandem mass spectrometry (GC-MS/MS) method 
was developed for quantitation of amino acid neurotransmitters, L-glutamic acid (GA) and γ- 
aminobutyric acid (GABA), in mouse whole brain. The developed method was used for 
measurement of whole brain concentrations of GA and GABA in a small subset of WT, Oat1-/-, 
and Oat3-/- mice at 3 and 18 mo. 
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CHAPTER 1 
 
 
 
 
 
EXPRESSION AND FUNCTION OF ORGANIC CATION AND ANION 
TRANSPORTERS (SLC22) IN THE CNS 
 
 
Drawn from manuscript published in Curr Pharm Des (2014) 20 (10): 1472-1486. 
 
 
 
 
 
1. A. INTRODUCTION 
 
 
The central nervous system is well insulated from changes in the systemic circulation. This 
compartmental isolation is achieved by anatomical (e.g., tight junctions) and biochemical (e.g., 
transporter proteins) mechanisms that exist in the blood-brain barrier (BBB) and the blood- 
cerebrospinal fluid barrier (BCSFB). The endothelial cells of the brain capillaries comprise the 
BBB, while the BCSFB is comprised of the choroid plexus (CP) epithelia along with the 
arachnoid villi and circumventricular organs. These tissues regulate the brain penetration and 
clearance of endogenous (e.g., neurotransmitters or metabolic waste-products) and xenobiotic 
(e.g., drugs or toxins/toxicants) substances, effectively controlling the composition of the 
extracellular fluid of the brain (interstitial fluid and CSF) and preserving the CNS milieu. Thus, 
identification of the transporters present in these barriers, and the properties that govern their 
function, is fundamental to understanding the maintenance of brain homeostasis and the basis 
for some disorders involving its perturbation. 
 
 
The physiological processes governing the movement of charged organic substances across 
epithelial and endothelial cell sheets have been studied for hundreds of years. By the late 
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1980’s and early 1990’s detailed models emerged summarizing the complex interplay between 
cellular energy, sodium, potassium and proton (H
+
) gradients, membrane potential, and 
dicarboxylate coupled transport that characterize the ‘classical’ renal organic cation and anion 
transport systems. Subsequently, the latter half of the 1990’s saw the cloning of the first ‘renal’ 
organic cation transporters (OCTs) and organic anion transporters (OATs). Detailed 
investigations using a variety of comparative organ models including renal slices, renal 
basolateral and brush border membrane vesicle preparations, isolated mammalian and killifish 
 
renal tubules, and intact rodent CP and brain capillaries, demonstrated that the physiological 
characteristics of organic cation and anion transport across each of these tissues was similar 
(Pritchard and Miller, 1993). It is now confirmed that ‘renal’ OCTs and OATs are expressed 
and function in barrier tissues throughout the  body  including  small  intestine,  liver, 
placenta, CP and brain capillaries. The OCTs and OATs are classified within the Solute 
Carrier (SLC) superfamily of transporters, which currently contains over 450 identified 
transporter proteins divided into ~52 transporter families. OCTs and OATs belong to the same 
SLC family, family 22 (SLC22), the organic cation/anion/zwitterion transporters. 
 
 
The purpose of this review is to present an overview of the current knowledge 
regarding OCT and OAT expression and function within the CNS. A brief introduction of 
the SLC22 family transporters presently thought to be relevant to brain capillary (BBB) and 
CP (BCSFB) function is provided, however, for an in-depth accounting of the original cloning, 
identification and characterization of members of the SLC22 transporter family the reader is 
referred to several recent reviews covering this aspect (Wright and Dantzler, 2004; Koepsell et 
al., 2007; VanWert et al., 2010). Perspective is given on how detailed investigation of active 
3  
renal organic solute transport fed our current understanding of CNS handling of organic cations 
and anions. The biochemical and functional evidence supporting OCT and OAT expression in 
the CNS compartment is summarized. 
 
 
 
1. B. ORGANIC CATION AND ANION TRANSPORTERS (SLC22) RELEVANT TO 
THE CNS 
 
Efficient neurotransmission requires the rapid removal of released neurotransmitters from 
the synaptic cleft in order to terminate neuronal signaling and prepare for the next event. For 
monoaminergic signaling, it is well established that members of the SLC6 transporter family 
expressed in the brain, namely the norepinephrine (SLC6A2), dopamine (SLC6A3) and 
serotonin (SLC6A4) transporters, represent Na
+
-dependent, high affinity (low capacity) 
neuronal uptake  pathways   to   clear   released   monoamine   neurotransmitters (Pacholczyk 
et al., 1991; Giros and Caron, 1993; Lesch et al., 1993; Kristensen et al., 2011). However, Na
+ 
independent transport of choline and catecholamines has been reported in brain/glial cells 
(Yamamura and Snyder, 1973; Friedgen et al., 1996; Russ et al., 1996; Streich et al., 1996). 
 
Now, a growing body of literature strongly supports the involvement of OCTs and OATs 
(SLC22) expressed in the CNS in the extraneuronal Na
+
-independent, low affinity (high 
capacity) clearance of neurotransmitters and their metabolites from the interstitial fluid/CSF 
and, thus, contributing to the termination of neurotransmission and the maintenance of CNS 
homeostasis. 
 
In vitro, cloned OCTs have been  demonstrated  to  interact  with  an  array  of 
structurally diverse compounds including endogenous amines that function in the CNS (i.e., 
choline,  dopamine,  epinephrine,  histamine,  norepinephrine,  and  serotonin)  and  therapeutic 
4  
agents that target the CNS (i.e., amphetamine, desipramine, fluoxetine, morphine, sertraline), 
raising the possibility that these transporters might function in the CNS (Table 1.1 and Table 
1.2) (Busch et al., 1996a; Busch et al., 1996b; Martel et al., 1996; Gorboulev et al., 1997; 
Zhang et al., 1997; Breidert et al., 1998; Grundemann et al., 1998; Kekuda et al., 1998; Wu et 
al., 1998a; Wu et al., 1998b; Murakami et al., 2000; Sweet et al., 2001; Amphoux et al., 2006; 
Zhu et al., 2012). In addition, some OATs were shown to interact with anionic catecholamine 
metabolites in vitro, including 3,4-dihydroxyphenylacetic acid (DOPAC), 4-hydroxy-3- 
methoxyphenylacetic acid (homovanillic acid, HVA), 5-hydroxyindole-3-acetic acid (5-HIAA), 
5-methoxy-3-indoleacetic acid, 3-methoxy-4-hydroxymandelic acid, 4-hydroxy-3- 
methoxymandelic acid and 3,4- dihydroxymandelic acid (Table 1.3) (Kusuhara et al., 1999; 
Sekine et al., 2000; Alebouyeh et al., 2003; Ohtsuki et al., 2003; Mori et al., 2004). Expression 
of OCTs and OATs has been detected in mouse, rat and human brain, consistent with their 
having a role in the disposition of these compounds in the CNS ( S w e e t  e t  a l . ,  2 0 0 1 ; 
S w e e t e t a l . , 2 0 0 2 ) . Furthermore, blockade of their transport function correlates with 
increased monoamines and/or their metabolites in the CNS compartment, e.g., peripheral 
administration of probenecid (a potent inhibitor of OATs) resulted in increased HVA and 5- 
HIAA levels in the CSF of mice, rats and humans (Roffler-Tarlov et al., 1971; Emanuelsson et 
al., 1987a; Emanuelsson et al., 1987b). 
  
Table 1.1. Interaction of monoamine neurotransmitters with organic cation transporters (SLC22). 
 
Compound Transporter Interaction System  Kinetics (mM) Reference 
    Km  Ki  IC50  
Dopamine rOct1 S HEK293 1.60±0.30    Amphoux et al 2006 
  S X. laevis 0.05     Koepsell 1998 
  S HEK293   1.10   Breidert et al 1998 
  S X. laevis 0.05±0.01    Busch et al 1996 
 rOct2 S HEK293 2.10±0.20    Amphoux et al 2006 
  S HEK293 2.10     Grundemann et al 1998 
  S X. laevis 0.65     Koepsell 1998 
  I HRPE     2.3±0.2 Wu et al 1998 
 hOCT2 S HEK293 1.40±0.20    Amphoux et al 2006 
  S HEK293 0.3±0.16    Busch et al 1998 
 rOct3 S HEK293 1.50±0.20    Amphoux et al 2006 
  I HRPE    0.62±0.04 Wu et al 1998 
 hOCT3 S HEK293 0.8     Zhu et al 2012 
  S HEK293 1.03±0.13    Duan & Wang 2010 
Histamine rOct1 I HEK293   1.4   Grundemann et al 1999 
 rOct2 S HEK293 0.89±0.14    Amphoux et al 2006 
  S HEK293 0.54  0.39   Grundemann et al 1999 
 rbOct2 I CHO    0.43±0.01 Suhre et al 2005 
 hOCT2 S HEK293 0.94±0.15    Amphoux et al 2006 
  S HEK293 1.3±0.3    Busch et al 1998 
  I CHO    3.3±0.05 Suhre et al 2005 
 rOct3 S HEK293 0.54±0.09    Amphoux et al 2006 
 hOCT3 S HEK293 0.22±0.06    Amphoux et al 2006 
  S HEK293 0.18  0.14   Grundemann et al 1999 
  S HEK293 0.64±0.24    Duan & Wang 2010 
Norepinephrine rOct1 S HEK293 0.80±0.25    Amphoux et al 2006 
  S HEK293   2.80   Breidert et al 1998 
 rOct2 S HEK293 2.10±0.40    Amphoux et al 2006 
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 Norepinephrine  
hOCT2 
rOct3 
hOCT3 
I 
S 
S 
S 
S 
S 
HRPE 
HEK293 
HEK293 
HEK293 
HRPE 
HEK293 
 
1.50±0.10 
1.9±0.6 
1.90±0.38 
0.4 
2.63±0.08 
 1.1±0.3 Wu et al 1998 
Amphoux et al 2006 
Busch et al 1998 
Amphoux et al 2006 
Wu et al 1998 
Amphoux et al 2006 
  S 
S 
S 
HEK293 
HEK293 
HEK293 
1.03 
0.92±0.17 
0.51 
  Zhu et al 2012 
Duan & Wang 2010 
Grundemann et al 1998 
Serotonin rOct1 
 
rOct2 
S 
S 
S 
HEK293 
HEK293 
HEK293 
0.90±0.50 
 
0.76±0.05 
 
0.65 
 Amphoux et al 2006 
Breidert et al 1998 
Amphoux et al 2006 
 rbOct2 
hOCT2 
I 
S 
CHO 
HEK293 
 
0.29±0.06 
 0.66±0.04 Suhre et al 2005 
Amphoux et al 2006 
  
rOct3 
hOCT3 
S 
I 
S 
I 
S 
HEK293 
CHO 
HEK293 
HRPE 
HEK293 
0.08±0.02 
 
00.50±0.10 
 
0.9 
  
0.31±0.02 
 
0.97±0.18 
Busch et al 1998 
Suhre et al 2005 
Amphoux et al 2006 
Wu et al 1998 
Zhu et al 2012 
  S HEK293 0.99±0.26   Duan & Wang 2010 
 
 
Compound Transporter Interaction System Kinetics (mM) Reference 
Km Ki IC50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
h, human; I, inhibitor; m, mouse; r, rat; S, substrate 
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Table 1.2. Inhibition of organic cation transporters by selective serotonin reuptake 
inhibitors (SSRIs). 
 
Compound Transporter Interaction System Kinetics (mM) Reference 
   Km Ki IC50  
Desipramine rOct1 I X. laevis 0.003  Grundemann 
et al 1994 
 hOCT1 I HEK293  0.002 Haenisch et 
al 2012 
  I HeLa 0.005  Zhang et al 
1998 
 hOCT2 I HEK293  0.075 Haenisch et 
al 2012 
  I X. laevis 0.016  Gorboulev 
et al 1997 
 rOct3 I HRPE  0.06 Kekuda et al 
1998; Wu et 
al 1998 
 hOCT3 I HEK293  0.072 Haenisch et 
al 2012 
  I HEK293  0.005 Zhu et al 
2012 
  I HRPE 0.014  Wu et al 
  2000   
Fluoxetine hOCT1 I HEK293  0.003 Haenisch et 
al 2012 
 hOCT2 I HEK293  0.029 Haenisch et 
al 2012 
 hOCT3 I HEK293  0.038 Haenisch et 
al 2012 
  I HEK293  0.022 Zhu et al 
  2012   
Imipramine hOCT1 I HEK293  0.018 Haenisch et 
al 2012 
 hOCT2 I HEK293  0.015 Haenisch et 
al 2012 
 hOCT3 I HEK293  0.054 Haenisch et 
al 2012 
  I HEK293  0.011 Zhu et al 
2012 
  I HRPE 0.042  Wu et al 
  2000   
Sertraline hOCT1 I HEK293  0.009 Haenisch et 
al 2012 
 hOCT2 I HEK293  0.026 Haenisch et 
al 2012 
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Compound Transporter Interaction System Kinetics (mM) Reference 
Km Ki IC50 
Sertraline hOCT3 I HEK293 0.026 Haenisch et 
al 2012 
I HEK293 0.007 Zhu et al 
2012 
a
h, human; m, mouse; r, rat 
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Substrate/Inhibitor Transporter Interaction System Kinetics (mM) Reference 
    Km Ki IC50  
DOPAC hOAT1 I S2   0.56±0.09 Alebouyeh 
et al 2003 
 hOAT3 I S2   0.99±0.10 Alebouyeh 
  et al 2003   
5-HIAA hOAT1 I S2   0.11±0.02 Alebouyeh 
et al 2003 
 hOAT3 I S2   0.91±0.03 Alebouyeh 
  et al 2003   
HVA hOAT1 I S2   0.07±0.01 Alebouyeh 
et al 2003 
 rOat3 S X. 
laevis 
0.27±0.1   Mori et al 
2003 
 hOAT3 I S2   0.76±0.09 Alebouyeh 
  et al 2003   
Kynurenic Acid mOat1 I COS-7   0.034 Bahn et al 
2005 
 hOAT1 S X. 
laevis 
0.005   Uwai et al 
2012 
 mOat3 I COS-7   0.008 Bahn et al 
2005 
 hOAT3 S X. 
laevis 
0.005   Uwai et al 
2012 
Quinolinic Acid mOat1 I COS-7    Bahn et al 
2005 
 mOat3 I COS-7    Bahn et al 
  2005   
Xanthurenic Acid mOat1 I COS-7   0.015 Bahn et al 
2005 
 mOat3 I COS-7   0.011 Bahn et al 
2005 
 
 
 
Table 1.3. Inhibition of organic anion transporters by neurotransmitter metabolites. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
h, human; m, mouse; r, rat 
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Following is a brief summary of the isolation, tissue expression profile and functional 
characterization of OCTs and OATs known to be expressed in the CNS: 
 
 
Organic cation transporter 1 (Oct1; Slc22a1). Cloned from rat kidney in 1994 
(Grundemann et al., 1994). Known orthologs in human, mouse and rabbit (Schweifer and 
Barlow, 1996; Zhang et al., 1997; Terashita et al., 1998; Green et al., 1999). Oct1 mRNA was 
detected in intestine, kidney and liver in mouse, rabbit and rat; also  in  CP,  skin  and 
spleen of rat and olfactory mucosa of mouse (Grundemann et al., 1994; Gorboulev et al., 
1997; Terashita et al., 1998; Green et al., 1999; Sweet et al., 2001; Slitt et al., 2002; Monte et 
al., 2004). In humans OCT1 expression was observed in heart, liver and skeletal muscle; lack 
of detection in human kidney may represent a true species difference ( Go rb o u l ev  et  al. , 
1 9 9 7 ;  Z h an g  et  al . ,  1 9 9 7 ) .  Membrane  depolarization,  but  not  the  presence  of  a  H
+
 
gradient, decreased rOct1 transport activity (Grundemann et al., 1994). Thus, mechanistically, 
rOct1 functions as a facilitated diffusion carrier, characteristic of the basolateral uptake step in 
renal proximal tubules. Subsequently, immunohistochemistry detected rOct1 signal in the 
basolateral membrane of renal proximal tubules and in the sinusoidal (basolateral) membrane 
of hepatocytes (Meyer-Wentrup et al., 1998; Urakami et al., 1998). 
 
 
Oct2  (Slc22a2).  Cloned  in  1996  from rat kidney ( O k u d a  e t  a l . ,  1 9 9 6 ;  W a l s h 
e t a l . , 1 9 9 6 ) . Orthologs identified in mouse, man, pig and rabbit (Gorboulev et al., 1997; 
Grundemann et al., 1997; Mooslehner and Allen, 1999; Zhang et al., 2002). Oct2 mRNA 
expression was mainly observed in kidney in human, mouse and rat (Okuda et al., 1996; 
Gorboulev et al., 1997; Slitt et al., 2002; Alnouti et al., 2006). Oct2/OCT2 mRNA was also 
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detected in CP of rats and murine olfactory mucosa (Sweet et al., 2001; Monte et al., 2004). 
Like rOct1,  rOct2-mediated  transport  was  significantly reduced by membrane depolarization 
and not stimulated by a trans-H
+  
gradient, again characteristic of the facilitated diffusion 
basolateral uptake  step  in  renal  proximal  tubules  ( W a l s h  e t  a l . ,  1 9 9 6 ;  S w e e t  a n d 
P r i t c h a r d , 1 9 9 9 ) . Subsequently, basolateral targeting of a rOct2-green fluorescent protein 
fusion construct in intact killifish renal proximal tubules and immunohistochemical staining of 
proximal tubule basolateral membranes in rat renal slices was observed (Karbach et al., 2000; 
Sugawara-Yokoo et al., 2000; Sweet et al., 2000). 
 
 
Oct3 (Slc22a3). Isolated from rat placenta in 1998 (Kekuda et al., 1998). Orthologs 
identified in human and mouse (Grundemann et al., 1998; Verhaagh et al., 1999). Oct3/OCT3 
mRNA expression exhibited a wide tissue distribution including adrenal gland, blood vessels, 
brain, CP, heart/aorta, intestine, kidney, lung, placenta, skeletal muscle and thymus (Kekuda 
et al., 1998; Verhaagh et al., 1999; Sweet et al., 2001; Slitt et al., 2002; Alnouti 
et al., 2006) . Hepatic Oct3/OCT3 message expression was strong in humans, but showed 
little to no expression in mouse and rat (Kekuda et al., 1998; Verhaagh et al., 1999; Slitt et al., 
2002; Alnouti et al., 2006). Rat Oct3-mediated transport was reduced when the potential- 
difference across the cell membrane was decreased and electrophysiology confirmed 
electrogenic transport of substrate organic cations (Kekuda et al., 1998). Thus, rOct3 also 
functions as a basolateral facilitated diffusion carrier in kidney. 
 
 
Organic cation/carnitine transporter (Octn1; Slc22a4). Cloned in 1997 from human 
liver (Tamai et al., 1997). Orthologs identified in mouse and rat (Tamai et al., 1997; Tamai et 
al., 2000; Wu et al., 2000).    Octn1/OCTN1 mRNA was detected in a number of tissues 
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including brain, CP, heart, intestine, kidney, liver, olfactory mucosa and spleen (Tamai et al., 
1997; Tamai et al., 2000; Wu et al., 2000; Sweet et al., 2001; Slitt et al., 2002; Monte et al., 
2004; Alnouti et al., 2006). Transport activity of all three Octn1/OCTN1 orthologs was 
stimulated by a trans-applied H
+  
gradient, with little to no effect of membrane potential, 
suggesting  it  was  an apical H
+
/organic  cation exchanger in kidney (Tamai et al., 1997; 
Yabuuchi et al., 1999; Tamai et al., 2000; Wu et al., 2000; Tamai et al., 2004). Subsequently, 
mOctn1 was immunolocalized to the apical membrane of renal proximal tubule (Tamai et al., 
2004). 
 
 
Octn2 (Slc22a5). Cloned from a human placental trophoblast cell line in 1998 (Wu et al., 
1998b). Mouse and rat orthologs have been isolated (Tamai et al., 1998; Wu et al., 1998b; 
Nezu et al., 1999; Wu et al., 1999). Octn2/OCTN2 mRNA was reported in a variety of tissues 
including brain (cerebellum, cortex, and hippocampus), CP, heart, intestine, kidney, liver, 
placenta,  and  testis  common  to  all  three  species  ( T a m a i  e t  a l . ,  1 9 9 8 ;  W u  e t  a l . , 
1 9 9 8 b ; W u e t  a l . , 1 9 9 9 ;  T a m a i  e t  a l . , 2 0 0 0 ;  S w e e t  e t  a l . , 2 0 0 1 ;  S l i t t  e t  a l . , 
2 0 0 2 ; A l n o u t i e t a l . , 2 0 0 6 ) . Expression also was seen in murine olfactory mucosa 
(Monte et al., 2004). Initial characterization showed Octn2/OCTN2- mediated transport was 
pH-dependent, but Na
+
-independent, suggesting an apical membrane localization (Wu et al., 
1998b; Tamai et al., 2000). Immunohistochemistry/immunoblotting confirmed mOctn2 protein 
expression in astrocytes and in renal brush border membrane vesicles and rOctn2 protein in 
astrocytes and neurons from adult rat cerebral cortex (Januszewicz et al., 2009; Cano et al., 
2010; Januszewicz et al., 2010). 
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Octn3 (Slc22a21). Identified in mouse in 2000 (Tamai et al., 2000). Murine Octn3 
message was found in kidney, olfactory mucosa, small intestine and testis (Tamai et al., 2000; 
Monte  et  al., 2004;  Duran  et  al., 2005;  Alnouti et  al., 2006). Na
+
-independent carnitine 
transport was observed for mOctn3 (Tamai et al., 2000) . Expression of mOctn3 protein in 
kidney, peroxisomes and testis was detected by Western blot and visualized directly in the 
apical  membrane  of  proximal   tubule   cells   in   tissues   sections   ( T a m a i    e t    a l . , 
2 0 0 0 ;   L a m h o n w a h    e t    a l . ,    2 0 0 3 ;    L a m h o n w a h    e t    a l . ,    2 0 0 5 ; 
C a n o e t a l . ,  2 0 1 0 ) .  Immunohistochemistry confirmed rOctn3 protein was expressed 
in astrocytes and neurons from adult rat cerebral cortex (Januszewicz et al., 2010). 
Immunoblotting detected putative hOCTN3 protein in HepG2 cells and peroxisomes 
(Lamhonwah et al., 2003; Lamhonwah et al., 2005). 
 
 
Organic anion transporter 1 (Oat1; Slc22a6). Isolated in 1997 from rat kidney (Sekine et 
al., 1997; Sweet et al., 1997). Orthologs known in C. elegans, flounder, human, mouse, pig 
and rabbit ( L o p e z - N i e t o e t  a l . ,  1 9 9 7 ;  W o l f f  e t  a l . ,  1 9 9 7 ;  C i h l a r  e t  a l . ,  1 9 9 9 ; 
G e o r g e  e t  a l . ,  1 9 9 9 ;  H o s o y a m a d a  e t  a l . ,  1 9 9 9 ;  R a c e  e t  a l . ,  1 9 9 9 ;  B a h n  e t 
a l . , 2 0 0 2 ; H a g o s e t a l . , 2 0 0 2 ) . Oat1 mRNA was strongly expressed in CP, kidney and 
olfactory mucosa of mouse and rat (Pacholczyk et al., 1991; Pritchard et al., 1999; Sweet et al., 
2002; Monte et al., 2004). Rat Oat1 transport activity was dose-dependently cis-inhibited and 
trans-stimulated by the dicarboxylate, glutarate (Sweet et al., 1997). This was consistent with it 
functioning as an organic anion/dicarboxylate exchanger, the final step in the proposed tertiary 
active transport system for basolateral renal organic anion uptake (Shimada et al., 1987; 
Pritchard, 1988). Accordingly, a rOat1-green fluorescent protein fusion construct was targeted 
to  the  basolateral  membranes  of  intact  renal  tubules  (Sweet  et  al.,  1999).  Subsequently, 
14  
basolateral targeting was observed in both human and rat kidneys by immunohistochemistry 
(Kojima et al., 2002; Motohashi et al., 2002; Cheng et al., 2012). 
 
 
Oat2 (Slc22a7). Originally cloned from rat liver in 1994, however no transport activity was 
identified (Simonson et al., 1994). In 1998, organic anion transport activity was demonstrated 
(Sekine et al., 1998). Mouse and human orthologs are known (Enomoto et al., 2002; Kobayashi 
et al., 2002b). Renal and hepatic mRNA expression was detected in human, mouse and rat; 
expression in CP was demonstrated for mouse and rat (Sekine et al., 1998; Sun et al., 2001; 
Buist et al., 2002; Enomoto et al., 2002; Kobayashi et al., 2002a; Kobayashi et al., 2002b; 
Sweet et al., 2002). Initial membrane localization studies generated species-specific results, 
with renal rOat2 localized apically in the medullary thick ascending limb and cortical 
collecting ducts, but hOAT2 targeted to the basolateral proximal tubule membrane (Enomoto et 
al., 2002; Kojima et al., 2002). Whether or not this represents a true species difference in 
targeting or unresolved technical issues is unclear. However, a recent report also observed 
hOAT2 in the basolateral domain of proximal tubules (Cheng et al., 2012). 
 
 
Oat3 (Slc22a8). Isolated in 1999 from rat brain (Kusuhara et al., 1999). Orthologs 
identified in human, mouse, pig and rabbit (Cha et al., 2001; Sweet et al., 2002; Zhang et al., 
2004). Oat3 mRNA was detected in brain capillaries, CP and kidney (Kusuhara et al., 1999; 
Cha et al., 2001; Sweet et al., 2002; Zhang et al., 2004). Low-level hepatic mRNA expression 
was reported in rat, but not in mouse (Buist et al., 2002; Kobayashi et al., 2002b; 
Sweet et al., 2002; Buist and Klaassen,  2004) . Kidneys isolated from Oat3 knockout 
mice exhibited loss of basolateral uptake of substrate organic anions, suggesting that mOat3- 
mediated uptake may be driven by organic anion/dicarboxylate exchange (Sweet et al., 2002). 
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Subsequent evaluation of mouse and rat Oat3 transport energetics, both in intact tissue and in 
 
vitro with cells co-expressing a Na
+ 
dicarboxylate cotransporter and Oat3, demonstrated 
Na
+
-dependent  trans-stimulation  by  glutarate  indicating  that  it  is  a  basolateral  organic 
anion/dicarboxylate exchanger (Sweet et al., 2003). Hepatic transport of examined organic 
anions was unaffected in the knockout animals. Basolateral staining for Oat3/OAT3 in rat 
and human renal proximal tubules has been observed by immunohistochemistry (Kojima et al., 
2002; Motohashi et al., 2002; Cheng et al., 2012). 
 
 
1. C. SLC22 TRANSPORTERS: FROM KIDNEY TO BRAIN 
 
 
As alluded to above, by the 1980’s detailed models describing the physiological 
characteristics of the pathways for movement of organic cations and anions across renal 
proximal tubule cells had been developed (Pritchard and Miller, 1993) . These models 
predicted the existence of proteins to mediate each step in the process, i.e., transporters 
(Figure 1.1). For example, entry of organic cations into a renal proximal tubule cell from the 
blood was demonstrated to be associated with the electrochemical gradient, with the 
membrane potential difference and resulting inside negative resting potential providing the 
major driving force, which suggested the presence of a facilitated diffusion transporter 
(uniporter) in the basolateral membrane (Pritchard and Miller, 1993). Exit of organic cations 
from the cell into the urinary space is energetically uphill and, thus, coupled to an exchange 
mechanism, e.g., for H
+
, suggesting the presence of an exchanger (antiporter) in the apical 
membrane (Pritchard and Miller, 1993). For organic anions, it is the entry step from the blood 
that is energetically uphill as the inside negative resting potential must be overcome (Figure 
1.1). Cellular energy input is utilized indirectly through a tertiary active process whereby (i) 
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the Na
+
/K
+
-ATPase maintains an inwardly directed Na
+ 
gradient (inhibited by ouabain), (ii) 
a  Na
+
/dicarboxylate  cotransporter  (symporter)  uses  the  inward  Na
+    
gradient  to  drive 
transport of a dicarboxylate into the cell (against its electrochemical gradient; inhibited by 
lithium or methylsuccinate), and (iii) an exchanger utilizes the  established  outwardly 
directed dicarboxylate gradient to drive cellular entry of the substrate  organic  anion 
(inhibited by probenecid) (Shimada et al., 1987; Pritchard, 1988; Pritchard, 1990). Similar to 
organic cation entry, facilitated  diffusion  is  a  major  mechanism  driving  the  apical  efflux 
of organic anions into the urine (Pritchard and Miller, 1993). Thus, cellular entry and exit 
of organic cations and anions was known to involve physiologically distinct processes and, 
presumably, distinct basolateral and apical transporter proteins for each pathway, establishing a 
tissue polarity of transport (Figure 1.1). 
 
Subsequently, expression assay activity screening of rat renal cDNA libraries led to the 
cloning of the first OCT, organic cation transporter 1  (rOct1,  slc22a1),  and  the  first 
OAT, organic anion transporter 1 (rOat1, Slc22a6) (Grundemann et al., 1994; Sekine et al., 
1997; Sweet et al., 1997). However, since the uptake and efflux steps utilize different 
physiological driving forces, simply knowing a protein mediated the transport of an organic 
cation or anion was insufficient to know where (basolateral or apical) to place it within the 
physiological model describing proximal tubule flux of organic solutes. Further 
characterization studies demonstrated that rOct1 was sensitive to changes in the membrane 
potential and, thus, represents the predicted basolateral facilitated diffusion carrier from the 
physiological proximal tubule model describing the organic cation transport system (Figure 
1.1). Work on rOat1 found its activity was linked to an endogenous outward dicarboxylate (α- 
ketoglutarate)    gradient    and    that    it    represents    the    predicted    basolateral    organic 
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anion/dicarboxylate exchanger from the physiological proximal tubule model (Figure 1.1). Of 
course, this was itself an oversimplification, and today there at least three known OCTs that 
operate via facilitated diffusion, Oct1/OCT1, Oct2/OCT2 and Oct3/OCT3, and at least three 
that utilize an exchange mechanism, Octn1/OCTN1, Octn2/OCTN2 and Octn3/OCTN3. 
Similarly, at least two OATs, Oat1/OAT1 and Oat3/OAT3, are conclusively identified as 
dicarboxylate exchangers, with the mechanisms driving Oat2/OAT2 transport activity still 
unclear. 
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Figure 1.1. Organic cation and anion transport systems involving SLC22 transporters in 
renal proximal tubule, choroid plexus and brain capillary cells.  The detailed physiological 
models describing the energetics of movement of organic cations (OC
+
) and organic anions 
(OA
-
) from the systemic circulation to urine through renal proximal tubule cells and from CSF to 
the systemic circulation through choroid plexus cells are depicted. Upper renal and plexus cells 
depict OC
+   
entry (from  blood or CSF, respectively) via a membrane  potential difference- 
sensitive facilitated diffusion mechanism and OA
-  
entry via a tertiary active process linking 
Na
+
/K
+
-ATPase, Na
+
/dicarboxylate symport (cotransporter), and dicarboxylate/OA
- 
antiport 
(exchanger) activities. Exit of OC
+ 
is largely accomplished by proton (H
+
)/OC
+ 
antiport 
(exchanger) linked to a Na
+
/H
+  
antiport (exchanger) activity. Notably, the same physiological 
driving forces govern the cellular entry and exit steps of these organic solutes in proximal tubule 
and choroid plexus, however, the components of each transport system target to the 
opposite sides of the cell (i.e., basolateral vs. apical) establishing a reversal in the tissue 
polarity of organic solute transport. For brain capillary cells the basal membrane is in contact 
with the CNS or brain side and the apical membrane is in contact with the systemic circulation, 
however, less is known  about the mechanisms  driving transport in this tissue and the 
available  SLC22 localization data are somewhat unclear in terms of polarity of expression and 
function in this tissue. Identified transporters associated with each of the physiological steps are 
identified (in lower cells for choroid plexus and proximal tubule). Currently, Oct1/OCT1, 
Oct2/OCT2 and Oct3/OCT3 are known facilitated diffusion carriers that support the cellular 
entry of OC
+  
and Octn1/OCTN1, Octn2/OCTN2 and Octn3/OCTN3 transport OC
+ 
out of the 
cell in exchange for OC
+ 
(carnitine) or H
+
. Oat1/OAT1 and Oat3/OAT3 are known exchangers 
that mediate cellular entry of OA
-
. Exit of OC
+  
and OA
-  
across the basolateral membrane of 
choroid plexus cells is less well understood, largely due to the difficulty in experimentally 
accessing this membrane, however, advances in imaging technology (both instrumentation and 
probes) are helping to move this area forward. Tissue accessibility has been a major obstacle to 
the study of brain capillary transport physiology as well. Recently, m,rOct2/hOCT2 protein 
expression was reported as “mainly” targeted to the apical membrane, however, there was 
apparent immunopositive signal associated with the basal membrane as well. Therefore, 
membrane targeting of these transporter orthologs in brain capillary is as yet unclear. Murine 
Octn1, mOctn2 and mOctn3 protein expression was detected in choroid plexus, however no 
specific membrane localization was reported. Human OAT2 protein localization in the 
basolateral membrane of renal proximal tubules has been observed, but Oat2/OAT2’s 
mechanism of transport remains unresolved. In the figure, an asterisk (*) denotes a transporter 
for which protein expression in human tissue has been reported. OC
+
, organic cation; OA
-
, 
organic anion; H
+
, proton; K
+
, potassium; Na
+
, sodium; α-KG, α-ketoglutarate; Ouab, ouabain- 
sensitive; Li
+
, MS, Li
+
- and MS-sensitive; Prob, probenecid-sensitive. 
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In addition to kidney, other barrier tissues, e.g., intestine, liver, placenta, brain capillaries 
and CP, actively transport organic cations and anions. In the CNS compartment, the choroid 
plexuses not only produce CSF, but also actively remove organic cationic and anionic 
compounds from the CSF and secrete them into the systemic circulation for eventual removal 
by the liver and/or kidneys. Thus, two fundamental questions were, (1) are the physiological 
mechanisms governing organic cation and anion transport across the brain capillaries and CP 
the same as those in kidney and (2) if so, are the same (or related) transporters that mediate this 
function in kidney also responsible for this activity in the brain capillaries and CP? 
 
 
1. D. CHOROID PLEXUS EPITHELIUM 
 
Similar to kidney, in vivo (intraventricular administration or  ventriculocisternal 
perfusion) and in vitro (isolated plexus) techniques provided physiological evidence that the CP 
(from cat, dog, goat, guinea pig,  rabbit  and  rat)  actively  removes  endogenous  and 
xenobiotic organic cations and anions from the CSF (Pappenheimer et al., 1961; Davson and 
Pollay, 1963; Tochino and Schanker, 1965b; Tochino and Schanker, 1965a; Hug, 1967; Neff et 
al., 1967). For example, benzylpenicillin, 2,4- dichlorophenoxyacetic acid, hexamethonium, 
HVA  (from  dopamine),  5-HIAA  (from  serotonin),  norepinephrine,  para-aminohippurate, 
phenolsulfonphthalein, morphine, methotrexate, N
1
- methylnicotinamide and salicylate, were 
all observed to accumulate in CP against their concentration gradients via saturable processes 
that were temperature sensitive and subject to inhibition (Pappenheimer et al., 1961; Davson 
and Pollay, 1963; Tochino and Schanker, 1965b; Tochino and Schanker, 1965a; Hug, 1967; 
Neff et al., 1967; Rubin et al., 1968; Cserr and VanDyke, 1971; Forn, 1972; Lorenzo and 
Spector, 1973; Pritchard, 1980). Furthermore, the peripheral administration of probenecid (a 
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known inhibitor of the renal organic anion transport system) blocked active efflux of 5-HIAA 
and HVA from rat and human brain (Neff et al., 1967; Roffler-Tarlov et al., 1971; 
Emanuelsson et al., 1987a; Emanuelsson et al., 1987b). Overall, it was concluded that the basic 
physiological characteristics of the clearance of ionized organic compounds from the CSF/brain 
were analogous to those identified in renal proximal tubules for clearance from blood. 
 
 
Subsequently, targeted mechanistic studies were performed in CP primary cell culture, 
membrane vesicle and intact tissue  systems  to  determine  if  the  molecular  energetics  of 
CP organic cation and anion transport were the same as those identified in kidney, e.g., 
dependence upon ion gradients or membrane potential difference (Figure 1.1). Mediated 
movement of the prototypical organic cation,  tetraethylammonium  (TEA),  across  the 
apical (ventricular) membrane of cultured rat primary CP epithelial cells was inhibited organic 
cations, demonstrated to be saturable, and energetically coupled to cellular metabolism 
(Villalobos et al., 1997; Villalobos et al., 1999). The estimated apparent Km for apical CP 
TEA transport in this system was 315 µM, a value similar to that obtained  for  TEA 
transport  (160-280  µM)  in  renal  basolateral  membrane  vesicles  ( U l l r i c h   e t   a l . , 
1 9 9 1 ; B r a a n d l e e t a l . , 1 9 9 2 ; V i l l a l o b o s e t a l . , 1 9 9 7 ) . When choline 
accumulation was investigated in this same system, movement across the apical membrane was 
found to be insensitive to manipulations that block tertiary active organic anion  transport, 
namely the removal of external Na
+  
or the addition of lithium chloride (Vill alob os et al., 
1999 ). However, transport was significantly reduced by depolarization of the membrane 
potential (characteristic of facilitated diffusion), but marginally affected by adjustments in pH, 
indicating  a  H
+  
exchange  mechanism  was  not  involved  ( V i l l a l o b o s  e t  a l . ,  1 9 9 9 ) . 
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Experiments conducted with intact rat CP in vitro also found that choline accumulation was 
insensitive to an imposed H
+ 
gradient, but significantly reduced by membrane depolarization 
( S w e e t e t a l . , 2 0 0 1 ) . Thus, movement of organic cations across the ventricular 
(apical)  membrane  of  CP  (CSF  to  blood  direction)  was  mechanistically  consistent  with 
 
basolateral organic cation uptake in renal proximal tubule cells (blood to urine direction). 
 
 
 
The mechanisms driving apical organic anion transport were investigated in bovine and 
rat CP ( P r i t c h a r d e t a l . , 1 9 9 9 ) . Accumulation of the organic anion, 2,4- 
dichlorophenoxyacetic acid, by intact bovine CP and bovine CP brush-border membrane 
vesicles,  was  stimulated  in  the  presence  of  dicarboxylate  (glutarate).  However,  this  cis- 
stimulation by dicarboxylate was only observed in the presence of Na
+ 
and was blocked by 
lithium or methylsuccinate (P rit ch ard et al., 1 999 ) . Further, when the membrane vesicles 
were preloaded with glutarate, a significant trans-stimulation of 2,4- dichlorophenoxyacetic 
 
acid   uptake,   which   was   insensitive   to   Na
+     
depletion   or   inhibition   by  lithium   or 
methylsuccinate, but sensitive to probenecid (OAT) inhibition, was observed (Figure 1.1). 
Thus,    when    dicarboxylate    (glutarate)    was    applied    externally,    inhibition    of    the 
Na
+
/dicarboxylate  cotransporter  by  either  removal  of  the  Na
+   
gradient  driving  force  or 
application of the inhibitors lithium or methylsuccinate, prevented transport of dicarboxylate 
into the vesicles for subsequent use in organic anion/dicarboxylate exchange (Pritchard et al., 
1999). If the need for Na
+
/dicarboxylate cotransporter activity was bypassed, i.e., by 
preloading the vesicles with glutarate, stimulation of organic anion uptake that was insensitive 
to inhibition by lithium or methylsuccinate occurred. Virtually identical results were obtained 
in  intact  rat  CP  (Pritchard  et  al.,  1999).  These  findings  paralleled  those  reported  for  p- 
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aminohippurate uptake by renal basolateral membrane vesicles (Shimada et al., 1987; 
Pritchard, 1988). Thus, movement of organic anions across the apical membrane of CP (CSF to 
blood direction) was mechanistically consistent with basolateral tertiary active organic anion 
uptake in renal proximal tubule cells (blood to urine direction). 
 
 
The first evidence that the ‘renal’ SLC22 transporters might also function in the CNS was 
obtained when PCR reaction products for Oct2, Oct3, Octn1 and Octn2, but not Oct1, were 
detected in rat CP (Sweet et al., 2001; Sweet et al., 2002) . PCR  also  confirmed 
message expression of Oat1, Oat2 and Oat3 in rat and mouse CP, indicating mRNA 
expression of all three organic anion transporter paralogs in both species (Sweet et al., 2001). 
To investigate membrane targeting of OCT and OAT proteins directly, fusion constructs of 
rOct2 and rOat1 with green fluorescent protein (GFP) were made (Sweet et al., 1999; Sweet et 
al., 2000). Mechanistic analysis of rOat1-mediated transport indicated that it was an organic 
anion/dicarboxylate exchanger and should be targeted to the basolateral membrane of renal 
proximal tubule cells (Sweet et al., 1997). Similar analysis indicated that rOct2 operated as a 
membrane potential-driven facilitated diffusion carrier, an activity also associated with the 
basolateral membrane of renal proximal tubule cells (Walsh et al., 1996; Sweet et al., 1999). 
Accordingly, when the rOat1-GFP or rOct2- GFP fusion proteins were expressed in intact, 
functional renal proximal tubules in vitro, marked basal and lateral membrane fluorescence 
was observed (Sweet et al., 1999; Sweet et al., 2000). In direct contrast to these results, 
when these constructs were transfected into intact rat CP in vitro, fluorescent signal was 
exclusively associated with the apical plexus membrane (Pritchard et al., 1999; Sweet et al., 
2001). Further, CP isolated from Oat3 knockout mice exhibited significantly impaired 
accumulation  of  organic  anions  in  vitro  ( S w e e t   e t   a l . ,   2 0 0 2 ;   S y k e s   e t   a l . , 
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2 0 0 4 ) . These studies exhaustively compared apical organic anion transport in CP from wild 
type and Oat3 knockout mice and conclusively demonstrated that mOat3 protein is expressed 
and functional, as well as targeted to the apical membrane, in CP (Sweet et al., 2002; Sykes et 
al., 2004). Functional and immunocytochemical investigations in rat CP confirmed apical 
membrane targeting of rOat3 (Nagata et al., 2002; Lowes et al., 2005). A recent study 
examining antiviral uptake in CP isolated from wild type, Oat1 knockout and Oat3 knockout 
mice also detected functional activity of mOat1 and mOat3 in the apical membrane (Nagle et 
al., 2013). This switch in ‘targeting polarity’ of these transporters between kidney and CP 
corresponds directly with the fundamental difference between systemic elimination via renal 
proximal tubule (transcellular movement of substrates from blood to urine) and CP 
mediated clearance from the CSF (transcellular movement of substrates from CSF to blood) 
is the order in which the basolateral and apical membrane domains are encountered by solutes. 
In kidney, cellular entry of substrates from the systemic circulation occurs across the 
basolateral membrane followed by efflux into the urine across the apical membrane, whereas, 
in CP cellular entry of substrates from the CSF occurs across the apical membrane followed by 
efflux into the blood across the basolateral membrane, i.e., functionally there is a difference in 
tissue polarity (Figure 1.1). Thus, if the same transporters that were identified to mediate this 
process in the renal proximal tubule, i.e., OCTs and OATs, were also responsible for this 
transport activity in CP, they would have to target to the opposite membrane in each of these 
cell types. Therefore, the observed reversal of membrane targeting for OCTs and OATs in CP 
(as compared to kidney) is in complete agreement with the functional data obtained for the 
cloned transporters examined in heterologous expression systems and for intact CP (Sweet et 
al., 1997; Pritchard et al., 1999; Sweet et al., 1999; Sweet et al., 2000; Sweet et al., 2001). 
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1. E. BRAIN CAPILLARY ENDOLTHELIUM 
 
Investigations into the physiological mechanisms controlling the transport of small organic 
cations (e.g., choline) and anions (e.g., benzylpenicillin) across the brain capillary endothelium, 
using isolated brain capillaries and a variety of primary and immortalized cell culture models, 
indicated that they were similar to those utilized by the kidney (Galea and Estrada, 1992; 
Sawada et al., 1999; Murakami et al., 2000; Allen and Smith, 2001; Kikuchi et al., 2003). 
Saturable,   energy-   dependent,    Na
+
-    and    pH-independent,    and    potential-sensitive 
mechanisms were demonstrated (Galea and Estrada, 1992; Sawada et al., 1999; Murakami et 
al., 2000; Allen and Smith, 2001). Messenger RNA expression of mOct1, rOct1, hOCT1, 
mOct2, rOct2 and hOCT2 was detected in isolated primary brain capillary endothelial cells 
( L i n e t a l . , 2 0 1 0 ) . Rat Oct1 and rOct2 were also seen in immortalized adult rat brain 
endothelial cells (ARBEC) (Lin et al., 2010). In marked contrast, a recent study failed to detect 
mOct1, mOct2 or mOct3 mRNA expression by quantitative PCR analysis in freshly isolated 
mouse brain capillaries (Andre et al., 2012). Western blotting and immunocytochemistry 
detected Oct1/OCT1 and Oct2/OCT2 protein expression in all three species (Lin et al., 2010). 
While it was concluded that these transporters were “mainly” expressed in the luminal 
membrane, each technique yielded Oct1/OCT1 and Oct2/OCT2 immunopositive signal 
associated with the basal membrane as well (Lin et al., 2010). In support of luminal targeting, 
siRNA knockdown of Oct1/OCT1 or Oct2/OCT2 in primary brain capillary endothelial cells 
resulted in significantly decreased apical organic cation transport (Lin et al., 2010). 
Moreover, simultaneous knockdown of both transporters yielded an even greater reduction 
in apical transport activity than the single knockdown of either transporter (Lin et al., 2010). 
In agreement with the lack of mOct3 mRNA expression in brain capillaries, no capillary 
associated fluorescence was observed by immunocytochemistry  in  brain  sections  ( A n d r e 
26  
e t a l . , 2 0 1 2 ) . Together, these data strongly support an active role for Oct1/OCT1 and 
Oct2/OCT2 in CNS permeation of organic cations, but further work is needed to fully resolve 
expression and function in this tissue in vivo. 
 
 
Octn2/OCTN2 mRNA expression also was observed in bovine and human primary brain 
capillary endothelial cells (Kido et al., 2001; Berezowski et al., 2004; Miecz et al., 2008). 
Immunohistochemistry revealed an Octn2 specific signal in the basal membrane of primary 
bovine brain capillary endothelial cells (Miecz et al., 2008). Murine Octn1, Octn2 and Octn3 
proteins appear to be expressed as a group in the cerebellum, CP, hippocampus, hypothalamus, 
motor cortex, olfactory bulb and spinal cord (Lamhonwah et al., 2008). In opposition to the 
reported basal targeting of bovine Octn2, functional analysis of carnitine transport across 
monolayers of primary bovine brain capillary endothelial cells yielded evidence supporting 
bovine Octn2 transport activity in both the basal (brain side) and apical (blood side) 
membranes ( K i d o e t a l . ,  2 0 0 1 ;  A n d r e  e t  a l . ,  2 0 1 2 ) . While there is an obvious need 
to better clarify the contribution of Octn/OCTN transporter function in the brain capillaries, 
expression in these brain regions is consistent with OCTN function being critical to cerebral 
energetics and neuronal support and protection. 
 
 
When examined in vivo using the brain efflux method, movement of OAT substrates such 
as benzylpenicillin, HVA, indoxyl sulfate, para-aminohippurate and thiopurines is mediated by 
an organic anion transport system physiologically similar to that in kidney (Ohtsuki et al., 
2002; Kikuchi et al., 2003; Mori et al., 2003; Mori et al., 2004). For example, the efflux of 
HVA from rat brain in vivo across brain capillaries was blocked by indoxyl sulfate, para- 
aminohippurate  or  benzylpenicillin,  suggesting  rOat3  expression  and  function  in  this 
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endothelium (Mori et al., 2003). Similarly, efflux from rat brain of the uremic toxin and OAT 
substrate, indoxyl sulfate, was inhibited by benzylpenicillin, para-aminohippurate or 
probenecid (Ohtsuki et al., 2002). PCR confirmed mRNA expression of Oat3 in brain 
capillaries of both mice and rats (Ohtsuki et al., 2002; Kikuchi et al., 2003; Ohtsuki et al., 
2004). In agreement with the functional and gene expression data, both mouse and rat Oat3 
proteins have been immunolocalized to the basolateral membrane (brain side) of brain 
capillaries in vivo (Kikuchi et al., 2003; Mori et al., 2003; Ohtsuki et al., 2004). Therefore, it is 
possible that Oat3/OAT3 dysfunction may contribute an as yet unrecognized component to 
various neurological conditions involving CNS imbalance. 
 
 
1. F. BEHAVIORAL CONSEQUENCES OF SLC DYSFUNCTION 
 
Oct3 knockout mouse.  Both  rOct3  and  hOCT3  were  simultaneously  demonstrated 
to possess properties consistent with the extraneuronal low affinity (high capacity) monoamine 
transport activity characterized in the CNS (Grundemann et al., 1998; Wu et al., 1998a). In 
support of this, Oct3 mRNA expression in the CNS compartment was reported in a number of 
brain regions in rats and mice including the area postrema, CP, dorsal raphe, medial 
hypothalamus, neurons of the cerebellum, hippocampus, substantia nigra and ventral 
tegmental area, subfornical organ and thalamus ( S w e e t  e t  a l . ,  2 0 0 1 ;  S c h m i t t  e t  a l . , 
2 0 0 3 ;  V i a l o u  e t  a l . ,  2 0 0 4 ; A m p h o u x  e t   a l . ,  2 0 0 6 ;   G a s s e r  e t   a l . ,  2 0 0 6 ; 
V i a l o u e t a l . , 2 0 0 8 ) . Neuronal and glial cell (astrocyte) expression of hOCT3 mRNA also 
has been reported (Inazu et al., 2006; Koepsell et al., 2007). More conclusively, mOct3 and 
hOCT3 protein expression was detected in astrocytes and nondopaminergic neurons within the 
nigrostriatal dopaminergic pathway and rOct3 protein immunoreactivity was observed in 
ependymal and glial-like cells in the dorsomedial hypothalamus, as well as in a number of 
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circumventricular organs, including the area postrema and subfornical organ (Inazu et al., 
2003; Vialou et al., 2004; Gasser et al., 2006). Murine Oct3 protein expression was also seen in 
the subfornical organ (Vialou et al., 2004). In agreement with immunodetection of mOct3 and 
hOCT3 in astrocytes, primary astrocytes isolated from Oct3 knockout mice exhibited about 
three-fold lower accumulation of substrate as compared to primary astrocytes isolated from 
wild type mice (Cui et al., 2009). Further, loss of mOct3 function, either by gene deletion or 
pharmacological blockade, was demonstrated to be neuroprotective (Cui et al., 2009). Thus, 
Oct3/OCT3 substrate specificity and protein expression are consistent with this transporter 
playing an important role in neurophysiology and neuropharmacology, particularly for CNS 
monoamine signaling. 
 
 
Initial investigation in Oct3 knockout mice detected a marked (~50%), albeit not 
significant, drop in steady-state dopamine and norepinephrine levels, but no overt 
physiological or neural dysfunction suggesting monoamine imbalance (Zwart et al., 2001). 
Recently, it was confirmed that dopamine transporter (DAT) protein levels are unchanged in 
these animals (Cui et al., 2009). When examined in the context of water and salt regulation, it 
was demonstrated that Oct3 knockout mice exhibit altered neural and behavioral responses to 
changes in blood osmolarity and regulation of salt ingestion, providing evidence that mOct3 
plays a functional role in the CNS (Vialou et al., 2004). A subsequent comprehensive survey of 
dopamine and serotonin (and their metabolites) levels in brains of Oct3 knockout mice 
revealed significant region-specific alterations (Vialou et al., 2008). For example, dopamine 
levels were markedly reduced (by ~46%) in the substantia nigra and ventral tegmental areas, 
and serotonin showed an ~12% drop in the pons. Decreases in other monoamines were also 
detected including an ~25% reduction in norepinephrine in the substantia nigra and ventral 
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tegmental areas and an ~20% drop in histamine level in the  hypothalamus and thalamus 
(Vialou et al., 2008). 
 
 
Despite these alterations in neurotransmitter levels, behavioral assessment with untreated 
animals found no differences between wild type and Oct3 knockout mice in basal locomotor 
activity, balance or coordination (Vialou et al., 2008). However, Oct3 knockout mice did show 
an elevated hyperlocomotor response to administered stimulants, e.g., amphetamine or 
cocaine ( K i t a i c h i e t a l . , 2 0 0 5 ; N a k a y a m a  e t a l . ,  2 0 0 7 ;  V i a l o u  e t a l . , 
2 0 0 8 ) . Recent microdialysis studies revealed that dopamine levels in Oct3 knockout mice 
treated with methamphetamine were increased 2-3-fold compared to similarly treated wild type 
mice indicating impaired dopamine clearance (Cui et al., 2009). In addition, Oct3 knockout 
mice exhibited less activity in the center zone (vs. wild type) during an open field 
activity test, suggestive of increased anxiety-like behavior (Vialou et al., 2008). This 
observation is in direct contrast to a separate study wherein it was concluded that Oct3 
knockout mice display a significantly decreased anxiety-like phenotype based upon 
performance in the elevated plus maze and open field tests (Wultsch et al., 2009). Oct3 
knockout mice roughly doubled the amount of time spent in the open arms of the elevated plus 
maze and displayed an almost four-fold increase in time spent in the center zone of an open 
field activity chamber. Resident-intruder (aggression) and Morris water maze (spatial memory) 
test results were similar between knockout and wild type mice (Wultsch et al., 2009). Clearly, 
further work is needed with this model to fully elucidate any connections between Oct3/OCT3 
dysfunction and deviant behaviors. 
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Using a knockdown approach, adult wild type mice given a seven-day infusion of antisense 
mOct3 oligonucleotides directly into the third ventricle exhibited reduced (by ~30%) 
expression of mOct3 protein in brain (Kitaichi et al., 2005). This downregulation of mOct3 
was associated with an enhanced locomotor response to methamphetamine (similar to Oct3 
knockout mice), decreased immobility during the forced swim test (i.e., decreased depression- 
like behavior), and a potentiated antidepressant response to imipramine (Kitaichi et al., 2005). 
All of these endpoints are consistent with the interpretation that mOct3 functions to remove 
released dopamine from the interstitial milieu, and when mOct3 activity is reduced/absent in 
the CNS, dopamine clearance is attenuated resulting in elevated levels of dopamine, enhancing 
dopaminergic neurotransmission and the associated behavioral  response(s).  When  a  three- 
day ventricular perfusion of  antisense  Oct3 oligonucleotides was performed in rats, 
reduction of rOct3 protein expression in the CP and ependymal cells was observed (Nakayama 
et al., 2007). As with the mice, decreased CNS expression of rOct3 resulted in significantly 
increased extracellular dopamine levels and hyperlocomotion response induced by 
methamphetamine administration (Nakayama et al., 2007). Furthermore, methamphetamine 
levels were significantly elevated in the CSF of rOct3 antisense treated animals (vs. wild type), 
possibly the result of decreased rOct3 activity in the CP. Together, these data strongly support 
a role for Oct3/OCT3 expressed in the CNS (neurons, glia, CP) in dopamine clearance and 
proper termination of catecholaminergic neurotransmission, and possibly in the efficacy of 
certain antidepressant medications. 
Pharmacological manipulation of OCT activity resulted in changes in other 
neurotransmitters as well. For example, the OCT inhibitor, decynium-22, produced a dose- 
dependent increase in  extracellular  serotonin  concentration  when  applied  to  the  medial 
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hypothalamus of rats ( F e n g e t a l . , 2 0 0 5 ) . This increase in serotonin correlated with 
altered specific behaviors such as increased grooming, suggesting that OCTs, and rOct3 in 
particular, function in the CNS and might play a role in adaptive neurophysiological and 
behavioral responses (Feng et al., 2005). Perfusion of the Oct3/OCT3 inhibitor, corticosterone, 
into the medial hypothalamus potentiated the response to fenfluramine administration in rats 
as measured by increased serotonin levels (Feng et al., 2009). Similarly, the norepinephrine 
metabolite, normetanephrine (Oct3 inhibitor), potentiated the response to venlafaxine in mice 
as evidenced by increased cortical extracellular norepinephrine (Rahman and Bardo, 2008). 
Behavioral results in a tail suspension test indicated this enhanced antidepressant-like effects 
(Rahman and Bardo, 2008). These results provide in vivo functional evidence not only in 
support of the “uptake 2 hypothesis,” wherein it was proposed that the concomitant inhibition 
of both uptake 1 (by SSRIs) and uptake 2 (by normetanephrine or other pharmacological 
agents) would result in a more rapid onset of antidepressant action (Schildkraut and Mooney, 
2004), but also of the concept that OCTs comprise the uptake 2 pathway component and, 
thus, represent critical targets for future development of drugs for mood disorder therapy. 
 
 
Investigations of OCT expression in SERT knockout mice found a significant increase 
in Oct3 mRNA expression in the hippocampus, but not in cortex, striatum, cerebellum or 
brainstem (Schmitt et al., 2003; Baganz et al., 2008). In the same animals, mOct1 mRNA 
expression remained unchanged (Schmitt et al., 2003; Baganz et al., 2008). 
Immunohistochemistry and immunoblotting confirmed mOct3 protein expression in the 
hippocampus, which was increased by 28% in SERT knockout mice (Baganz et al., 2008). 
Similar to the earlier studies performed in rats, quantification of serotonin clearance 
demonstrated that hippocampal OCT inhibition (via application of the inhibitors decynium-22 
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or corticosterone) was without effect in wild type mice, but produced significant reduction in 
serotonin clearance in SERT knockout mice (Baganz et al., 2008). Complementary to this 
evidence, clearance of the Oct3/OCT3 substrate, histamine, was significantly increased in the 
hippocampi of SERT knockout mice as compared to wild type (Baganz et al., 2008). Finally, it 
was shown that decynium-22 inhibition of serotonin clearance produced antidepressant-like 
effects in SERT knockout, but not in wild type mice (Baganz et al., 2008). Together, these 
data indicate that increased Oct3/OCT3 protein expression may represent compensatory 
mechanism in response to dysfunctional serotonin clearance. 
 
 
Oct2 knockout mouse. Rat Oct2 mRNA expression in the CNS compartment was 
reported to be associated with regions along the brain-CSF barrier, cerebellum, CP, 
hippocampus and leptomeninges (Sweet et al., 2001; Amphoux et al., 2006). Murine Oct2 
protein expression was observed in the amygdala, dorsal raphe, frontal  cortex  and 
hippocampus, specifically associated with noradrenergic and serotonergic neurons ( B a c q  e t 
a l . , 2 0 1 2 ) . Thus, some overlap with mOct3 expression might occur, however, no mOct2 
protein was detected in the substantia nigra or ventral tegmental area (Bacq et al., 2012). 
Neuronal expression of hOCT2 mRNA and protein was observed in the cerebral cortex and 
subcortical nuclei (Busch et al., 1998). In addition, hOCT2 transport activity, but not that of 
DAT, was inhibited by amantadine at clinical concentrations used in the treatment of 
Parkinson’s disease (Busch et al., 1998). Thus, hOCT2 expression, as well as substrate 
specificity and affinities (particularly for monoamines), is also consistent with it playing a key 
role in CNS physiology, monoamine signaling, and drug efficacy. For example, it was 
suggested that the therapeutic action of the antiparkinsonian drug, amantadine, might involve 
inhibition of hOCT2-mediated dopamine uptake (Busch et al., 1998). 
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Cell suspensions derived from cortex and hippocampus of Oct2 knockout mice exhibited 
markedly decreased norepinephrine and serotonin uptake as compared to suspensions from 
wild type mice, while dopamine uptake was unaffected ( B a c q e t a l . , 2 0 1 2 ) . Notably, 
protein expression levels of the norepinephrine transporter, serotonin transporter, and Oct3 
were comparable between Oct2 knockout and wild type animals. In contrast to Oct3 knockout 
mice, dopamine levels between wild type and Oct2 knockout mice were similar. Like Oct3 
knockout mice, a significant reduction in norepinephrine was found, however, the reduction in 
Oct2 knockout animals was associated with the cortex (~38%), hypothalamus (~22%), brain 
stem, cerebellum, hippocampus and striatum, not the substantia nigra and ventral tegmental 
areas ( B a c q e t a l . , 2 0 1 2 ) . Serotonin levels were reduced in the hippocampus (~19%), 
hypothalamus (~27%) and striatum (~20%). These changes did not lead to any overt 
differences in basal locomotor activity in Oct2 knockout mice (Bacq et al., 2012). 
 
 
When examined in behavioral models used to assess anxiety, Oct2 knockout mice 
appeared to exhibit a decreased anxiety phenotype, as measured by a 2-3-fold increase in time 
spent, and activity in, the center zone (open field and elevated O maze) and decreased (by 40- 
50%) latency period to feed (novelty suppressed feeding) (Bacq et al., 2012). Significantly 
increased immobility time was observed in both forced swim and tail suspension tests, 
suggestive of increased despair and, hence, an increased depressive-like phenotype. These data 
are consistent with Oct2/OCT2 playing an active role in norepinephrine and serotonin 
clearance from the brain interstitial fluid and, perhaps, from the CSF via the CP. Similar to the 
Oct3 knockout mice, Oct2 knockout animals showed an increased sensitivity (vs. wild type) to 
the acute effects of antidepressants. Venlafaxine and reboxetine were each observed to induce 
significant dose-dependent decreases in immobility time in the forced swim test (Bacq et al., 
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2012). Moreover, in the corticosterone induced depression model, unlike wild type animals, 
Oct2 knockout mice did not respond to long-term antidepressant (venlafaxine) treatment, 
indicating Oct2/OCT2 function was required for this effect ( B a c q e t a l . , 2 0 1 2 ) . 
Identification of these interactions might  be  the  first  steps  toward  new  clinical insight to 
the interindividual variation in patient response to antidepressant and anxiolytic drugs. 
 
 
1. G. FUTURE DIRECTIONS 
 
Normal brain function can be readily perturbed by improper clearance of metabolic waste 
products, neurotransmitters and xenobiotic toxins/toxicants. The extrarenal expression and 
function of the ‘renal’ OCTs and OATs in the CP and brain capillaries underscores their 
potential to impact CNS homeostasis and neurotoxicity through active clearance 
mechanisms. Further studies are needed to fully elucidate the role of SLC22 transporters in 
these processes. Currently, virtually nothing is known about transporters in the arachnoid villi 
and circumventricular organs, and the preliminary SLC22 transporter expression profiles 
reviewed herein are clearly suggestive of a role for these transporters in mediating organic 
solute flux in these (and other) CNS tissues. In addition, the pia mater is situated between the 
interstitial fluid of the brain and the CSF in the ventricles and what effect(s) this membrane has 
on the movement of OCT and OAT substrates between these compartments remains relatively 
unexplored. 
 
 
Intriguing data regarding the potential involvement of SLC22 transporters in the etiology of 
psychostimulant abuse has come to light. Cocaine, 3,4-methylenedioxy-N- 
methamphetamine (ecstasy), methamphetamine and phencyclidine (PCP) all have been 
demonstrated to inhibit Oct1/OCT1, Oct2/OCT2, Oct3/OCT3 and Octn2/OCTN2 (Wu et al., 
35  
1998a; Rytting and Audus, 2005; Amphoux et al., 2006). Recently, both the genotype and 
allele frequency of two independent single nucleotide polymorphisms identified in hOCT3 
were found to have significant associations with polysubstance use in subjects with 
methamphetamine dependence (Aoyama et al., 2006). A separate study identified two different 
novel independent mutations in hOCT3 exclusively in patients suffering from obsessive- 
compulsive disorder (Lazar et al., 2008). One was in the gene promoter and significantly 
increased expression (by ~36%) in vitro and the second was in the coding region (non- 
synonymous Met370Ile mutation) that conferred an ~40% loss in transporter function (Lazar et 
al., 2008). Thus, the development of selective hOCT2 and/or hOCT3 ligands might be 
efficacious in the treatment of disorders related to drug abuse and schizophrenia (Nakayama 
et al., 2007; Taubert et al., 2007; Cui et al., 2009). Further exploration of the nature and 
magnitude of hOCT2 and/or hOCT3 interactions with anxiolytics and antidepressants are 
needed to determine whether or not these transporters represent a previously unrecognized 
component of their pharmacological and therapeutic effects and/or novel pharmacological 
targets for new drugs. Indeed, recently the “uptake 2 hypothesis” was proposed wherein it 
was suggested that giving a drug that inhibited the extraneuronal uptake of monoamines (either 
directly or indirectly) in combination with standard reuptake inhibitors, or a single drug that 
targets both uptake systems, would ‘speed up’ the onset of their clinical effects (Schildkraut 
and Mooney, 2004). Preclinical findings with normetanephrine (metabolite of norepinephrine 
that inhibits OCTs) administered in combination with venlafaxine support this hypothesis 
(Rahman and Bardo, 2008) 
 
 
The endogenous CNS compounds salsolinol and cyclo(his-pro) have been identified as 
substrates  of  hOCT2  (Taubert  et  al.,  2007).  Salsolinol,  and  its  derivative  N-methyl-(R)- 
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salsolinol, are thought to be integral to the pathogenesis of Parkinson’s disease, as their 
concentrations were elevated in the CSF of Parkinson’s patients (Antkiewicz-Michaluk et al., 
1997; Naoi et al., 2002). Salsolinol cytotoxicity was significantly increased in cells expressing 
hOCT2 (vs. mock transfected or hOCT1- or hOCT3-expressing cells) and pretreatment with 
cyclo(his-pro) was protective (Taubert et al., 2007). Thus, hOCT2 expressed in the CNS, 
particularly in neurons, might be charged with maintaining the proper balance between 
intracellular concentrations of salsolinol and cyclo(his-pro), which in turn might be integral to 
dopaminergic neuronal health (Taubert et al., 2007). Any disruption of this balance could then 
trigger  nigral  neural  degeneration   and  the   development   of  Parkinson’s-like  symptoms. 
Similarly, the xenobiotic neurotoxin, 1-methyl-4-phenylpyridinium  (MPP
+
), induced severe 
Parkinson-like symptoms in humans and non-human primates (Langston et al., 1983; 
Langston and Ballard, 1984; Langston et al., 1984) and has been identified as a 
substrate of human, mouse and rat Oct1/OCT1, Oct2/OCT2 and Oct3/OCT3 (Martel et al., 
1996; Gorboulev et al., 1997; Zhang et al., 1997; Wu et al., 1998a; Wu et al., 2000; Hayer- 
Zillgen et al., 2002). Application of OCT inhibitors prevented MPP
+
-mediated cytotoxicity in 
human neurons and astrocytes, as well as in adult rat brain endothelial cells (Shang et al., 2003; 
Inazu et al., 2006; Liou et al., 2007). Clearly, tissue expression and functional properties of the 
SLC22 transporters are consistent with their playing a role in modulating 
neuroprotection/neurodegeneration and, thus, their continued  study  might  provide  new 
insight to CNS pathologies including seizures, Parkinson’s, and Reye’s syndrome. 
 
 
Overall,  it  is  intriguing  to  speculate  that  OCT-  and  OAT-mediated  clearance  of 
catecholamines and their metabolites from brain interstitial fluid by capillaries, neurons and 
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astrocytes, and from the CSF by the CP, plays a vital role in the termination of catecholamine 
signaling in the CNS. Several other tryptophan metabolites, i.e., anthranilic acid, kynurenic 
acid, picolinic acid, quinolinic acid and xanthurenic acid, have been identified as inhibitors of 
mOat1 and mOat3 as well (Bahn et al., 2005). In addition to expression and function of rodent 
Oat1 and Oat3 orthologs in CP and brain capillaries, immunostaining of mOat1 was observed 
in neurons in the cerebral cortex and hippocampus (Bahn et al., 2005). Thus, further 
exploration of the interactions between these tryptophan metabolites and the OATs will 
undoubtedly confer broader scope to the role of OAT expression and function in CNS 
homeostasis. Whether or not these observations are indicative of the SLC22 transporters being 
novel targets for the development of CNS-acting anxiolytics, antidepressants or other 
therapeutics for behavioral disorders is just beginning to be explored. What impact, if any, age, 
environmental conditions, pathological conditions, nutritional status, reproductive status, etc. 
have on SLC22 expression and/or function are additional areas that remain to be examined in 
greater detail. 
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CHAPTER 2 
 
 
 
RESEARCH HYPOTHESES AND SPECIFIC AIMS 
 
 
 
 
A. HYPOTHESIS 
 
 
2.A.1. The loss of Oat1 and/or Oat3 transporters in the murine CP results in altered 
concentrations of catecholamines (i.e. dopamine (DA), norepinephrine (NE), serotonin (5-HT)) 
and relevant metabolites (i.e. 3,4-dihydroxyphenylacetic acid (DOPAC), homovanilic acid 
(HVA), 5-hydroxyindole acetic acid (5-HIAA), quinolinic acid (QA), nicotinic acid (NA), and 
xanthurenic acid (XA)). 
 
 
2.A.2. The loss of Oat1 and/or Oat3 transporters in the murine CP results in altered anxiety-like 
and depressive-like behaviors known to associated with monoaminergic neurotransmission. 
 
 
2.A.3. The loss of Oat1 and/or Oat3 transporters in the murine CP results in altered 
concentrations of amino acid neurotransmitters GA and GABA. 
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2.B SPECIFC AIMS TO ADDRESS THE ABOVE HYPOTHESIS 
 
 
2.B.1. SPECIFIC AIM 1 
 
 
1. To develop a simple and rapid high performance liquid chromatography- 
ultraviolet/electrochemical detection method for the quantitation of monoamine 
neurotransmitters, dopamine (DA), norepinephrine (NE), and serotonin (5-HT), and relative 
metabolites (3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxy- 
3-indoleacetic acid (5-HIAA), quinolinic acid (QA), nicotinic acid (NA), and xanthurenic acid 
(XA)) in mouse whole brain tissue. A method validation will be conducted to evaluate linearity, 
limits of detection (LOD), lower limits of quantitation (LLOQ), sensitivity, selectivity, intra-day 
and inter-day accuracy and precision, recovery, and stability. 
2. To apply the developed method for the measurement of whole brain concentrations of the 
monoamine neurotransmitters and relative metabolites in WT, Oat1-/-, and Oat3-/- mice at 3, 6, 9, 
12, 15 and 18 mo. of age. 
 
 
2.B.2. SPECIFIC AIM 2 
 
 
1. To characterize the basal locomotor behavior, anxiety-like behavior, and depressive-like 
behavior of mice of the three genotypes (WT, Oat1-/-, and Oat3-/-) across age (3, 6, 9, 12, 15 and 
18 mo. of age) using commonly employed behavioral paradigms (e.g. open field activity (OFA), 
light-dark (LD), marble burying (MB), and tail suspension test (TST)). 
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2.B.3  SPECIFIC AIM 3 
 
 
1. To develop a simple and sensitive novel gas chromatography tandem mass spectrometry (GC- 
MS/MS) method for the quantitation of amino acid neurotransmitters, L-glutamic acid (GA) and 
γ-aminobutyric acid (GABA), in mouse whole brain tissue. A complete method validation will 
be conducted to evaluate linearity, limits of detection (LOD), lower limits of quantitation 
(LLOQ), sensitivity, selectivity, intra-day and inter-day accuracy and precision, instrument 
injector precision, derivatization efficiency, and stability. 
2. To apply the developed method for the measurement of whole brain concentrations of the 
amino acid neurotransmitters, GA and GABA, in a small subset of WT, Oat1-/-, and Oat3-/- mice 
at 3 mo. and 18 mo. of age. 
41  
 
 
CHAPTER 3 
 
 
 
A SIMPLE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD FOR 
THE SIMULTANEOUS DETERMINATION OF MONOAMINE 
NEUROTRANSMITTERS AND RELATIVE METABOLITES WITH APPLICATION 
IN MOUSE BRAIN TISSUE 
 
 
Drawn from manuscript published in Journal of Liquid Chromatography and Related 
Technologies, 2014 
 
 
 
 
 
3.A. INTRODUCTION 
 
Catecholamines (e.g. dopamine, norepinephrine) and indoleamines (e.g. serotonin (5- 
hydroxytryptamine)) are widely distributed neurotransmitters in the central nervous system 
(CNS) that play an important role in physiological and behavioral processes (i.e. sleep, reward 
and/or reinforcement, motor and cognitive functions, and neurobehavioral disorders) (Carlsson, 
1987; Greengard, 2001). Imbalance in CNS levels of these neurotransmitters and their 
metabolites is associated with a multitude of human neuropsychiatric conditions including 
anxiety, depression, panic disorder, schizophrenia and Parkinson’s disease (Carlsson and 
Carlsson, 1990; Boyer, 2000). The structure and simplified metabolic pathways are shown in 
Figure 3.1. The association between CNS concentrations of biogenic amines and the persistence 
of these neuropsychiatric conditions has been studied for almost 50 years with little 
improvement in diagnosis, treatment and clinical outcome, let alone the basic understanding of 
the underlying biochemical mechanisms involved. Recent advances in the knowledge of organic 
solute transporter tissue distribution and function have suggested a previously unrecognized role 
for  Solute  Carrier  family  22  (SLC22)  members  in  the  maintenance  of  CNS  monoamine 
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homeostasis (VanWert et al., 2010; Wang and Sweet, 2013; Farthing and Sweet, 2014). Various 
SLC22 transporters are expressed and functional in brain capillaries (blood-brain barrier), 
choroid plexus (blood-cerebrospinal fluid barrier), astrocytes and neurons (Farthing and Sweet, 
2014). Therefore, accurate quantitation of these monoamine neurotransmitters and their 
metabolites is essential, not only to advance our understanding of disease states regulated by 
aminergic neurotransmission and evaluation of novel pharmacotherapies for treating these 
disorders, but also for the assessment of potential involvement of SLC22 family members in 
maintaining CNS monoamine homeostasis. 
43  
 
 
Figure 3.1. Structures and simplified metabolic pathways for monoamine and indoleamine 
neurotransmitters in the CNS 
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Various analytical methods have been investigated for determining the level of 
catecholamine neurotransmitters and their metabolites in biological samples such as plasma, 
urine, and rodent brain (mouse, rat) (Mashige et al., 1994; Fauler et al., 1997; Lakshmana and 
Raju, 1997; Wang et al., 1999; Chan and Ho, 2000; Tornkvist et al., 2004). These include high 
performance liquid chromatography (HPLC) coupled with fluorescence, electrochemical (ECD), 
or mass spectrometry (MS) detection, as well as gas chromatography coupled with MS 
(Mashige et al., 1994; Fauler et al., 1997; Lakshmana and Raju, 1997; Wang et al., 1999; Chan 
and Ho, 2000; Tornkvist et al., 2004). HPLC fluorescence detection required cumbersome 
sample treatments, including a harsh two-step reaction using benzylamine and 1,2- 
diphenylethylenediamine in weakly alkaline media in the presence of potassium 
hexacyanoferrate (III) with heating to 50°C for 20 min, in order to generate fluorescent 
monoamine derivatives (Lakshmana and Raju, 1997). Previous HPLC methods coupled to ECD 
included reductive electrochemical detection to evaluate various monoamine neurotransmitters 
and metabolites in cerebrospinal fluid and brain tissue (Schmidt et al., 1990), however, when we 
evaluated reductive electrochemical detection using our current method, we found that not all of 
our components of interest were reducible. While methodology yielding very sensitive (LOD = 
fmol range) detection of catecholamines was reported, the analytical run time was 
approximately 45 min and we found that we did not need such sensitivity at the whole brain 
level (Sarre et al., 1992). There are several reported methods utilizing capillary electrophoresis 
with ECD for such determinations, but they also suffer from extended analytical run time (~40 
min) or inability to quantitate all of the components simultaneously, as achieved by our 
currently developed method (Jin et al., 1999; Parrot et al., 2007).  A recent method utilized ECD 
to  determine  the  concentration  of  catecholamines,  kynurenine,  and  indole  derivatives  of 
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tryptophan in rat brain tissue homogenate with a simple sample preparation, but this method 
also required an extensive analytical run time (~20 min) and the use of high electrode potentials 
for some of the analytes, which can be damaging to the electrochemical cells over time 
(Vaarmann et al., 2002). 
 
 
One method describing analysis of the kynurenine metabolites from the tryptophan 
pathway (i.e. quinolinic acid, nicotinic acid, and xanthurenic acid) was conducted with the use 
of simultaneous ultraviolet and fluorimetric detection requiring a derivitization step, as 
compared to the proposed simple sample preparation of the current method, and was only 
described in aqueous clean solutions (Presits and Molnar-Perl, 2003). Additional methods to 
quantify these metabolites utilizing HPLC with simultaneous ultraviolet-fluorimetric detection 
have been described in human and rat sera, but none to our knowledge in whole brain tissue 
homogenate (Badawy and Morgan, 2010; Zhao et al., 2011). HPLC coupled with MS, which 
can be used to identify analytes on the basis of their mass-to-charge (m/z) ratios, is a popular 
and powerful technique for analyzing neurotransmitters and their metabolites in several 
biological fluids (Chan and Ho, 2000; Tornkvist et al., 2004; de Jong et al., 2009; Liao et al., 
2010; Zhu et al., 2011; Moller et al., 2012). However, MS methods are highly complex, 
expensive to perform and require ready access to specialized (and expensive) instrumentation. 
 
 
Here we report the development of a simple and cost effective method for the sensitive 
and reproducible determination of three monoaminergic neurotransmitters (dopamine, 
norepinephrine, serotonin) and relevant metabolites (3,4-dihydroxyphenylacetic acid, 
homovanillic acid, 5-hydroxyindoleacetic acid, quinolinic acid, xanthurenic acid, nicotinic acid) 
in mouse brain homogenates with HPLC-UV/ECD.   This HPLC-UV/ECD method introduces 
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several advantages over previous methods in that it uses relatively inexpensive mobile phase 
constituents, requires minimal sample preparation and small injection volume while preserving 
good chromatographic separation. 
 
 
 
 
3.B. EXPERIMENTAL 
 
3.B.1. Chemicals and Reagents 
 
ACS reagent grade or higher purity dopamine, norepinephrine, serotonin (5- 
hydroxytryptophan), 3,4-dihydroxyphenylacetic acid, 5-hydroxyindoleacetic acid, homovanillic 
acid, 3,4-dihydroxybenzylamine, quinolinic acid and nicotinic acid were purchased from Sigma- 
Aldrich (St. Louis, MO, USA). Xanthurenic acid was purchased from Acros Organics (Fair 
Lawn, NJ, USA). For mobile phase preparation, sodium dihydrogen phosphate (monohydrate), 
acetonitrile (HPLC grade), phosphoric acid (99%), and triethylamine (HPLC grade) were 
purchased from Thermo Fisher Scientific (Fair Lawn, NJ, USA). EDTA was purchased from 
EM Science (Gibbstown, NJ, USA) and 1-octanesulfonic acid was purchased from JT Baker 
(Center Valley, PA, USA). An elution solution used to prepare standards and controls, and for 
tissue homogenation, consisted of phosphoric acid (0.5%) and acetic acid (1%) (Thermo Fisher 
Scientific, Fair Lawn, NJ, USA) and deionized water. Ultrapure deionized water (18 megohm- 
cm) was prepared daily using a Milli-Q Integral Water Purification System from EMD Millipore 
(Billerica, MA, USA). 
 
 
3.B.2 HPLC Equipment and Mobile Phase 
 
The Agilent 1200 series HPLC equipment consisted of a degasser (Model G1322A), 
solvent   delivery  system   (quaternary)   (Model   G1311A),  autosampler  (Model   G1329A), 
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thermostatted column compartment (Model G1316A), variable wavelength detetctor (Model 
G1314D) (Agilent Technologies, Santa Clara, CA, USA), and a Coulochem III electrochemical 
detector (Thermo Fisher Scientific (ESA Inc), Fair Lawn, NJ, USA). The analytical column 
used was an HR-80 C18 (80 mm x 4.6 mm I.D) (Thermo Fisher Scientific (ESA Inc)) coupled to 
a C18 guard column (12.5 mm x 4.6 mm I.D.) (Phenomenex®, Torrance, CA, USA). The guard 
column was replaced after each analytical run of approximately 50 brain tissue homogenate 
samples. The mobile phase was prepared following ESA, Inc. MD-TM mobile phase technical 
note and consisted of 75 mM sodium dihydrogen phosphate (monohydrate), 1.7 mM 1- 
octanesulfonic acid sodium salt, 25 μM EDTA, 10% acetonitrile and 1% triethylamine with a 
final pH of 3.0 adjusted using concentrated phosphoric acid (H3PO4). The mobile phase is 
commercially available by ESA, Inc.; however, to reduce expenses, it was prepared in house 
following the technical note for all experiments. A flow rate of 1 mL/min was used with typical 
HPLC operating pressure of approximately 145 bar and column temperature held at 25°C within 
the thermostatted column compartment. A 20 µL injection volume of the prepared tissue 
homogenate sample was accomplished using the Agilent 1200 series Model G1329A 
autosampler. Component detection was achieved using Agilent Variable Wavelength Detector 
set to 260 nm coupled to a Coulochem III Electrochemical Detector with the guard cell set to 
+0.05 V, an E1 voltage of 0 V and an E2 voltage of +0.6 V. This was chosen to be the potential 
at which the maximum response was given with the lowest amount of background noise for the 
majority of analytes detected using ECD (Figure 3.2). The detector was operated at high 
sensitivity setting with a 1 s response time. Peak height was used for computations. 
Concentrations of analytes were calculated by interpolation of their respective standard curves. 
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Data acquisition and component computations were performed using ChemStation™ software 
(Agilent Technologies, Santa Clara, CA, USA). 
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Figure 3.2. Voltammograms for norepinephrine, dopamine, serotonin, 3,4- 
dihydroxyphenylacetic acid, 5-hydroxyindoleacetic acid, and homovanillic acid at various 
oxidation potentials (+0.1,+0.2, +0.3, +0.4, +0.5, +0.6 V) 
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3.B.3. Standard and Control Preparation 
 
Stock standards of serotonin, dopamine, norepinephrine, 3,4-dihydroxyphenylacetic 
acid, nicotinic acid, quinolinic acid, and the internal standard 3,4-dihydroxybenzylamine (1.0 
mg/mL) were prepared in an “elution solution” consisting of phosphoric acid (0.5%), acetic acid 
(1%) and deionized water. Xanthurenic acid was prepared in the elution solution and required a 
few drops of 1N NaOH to go into solution. Homovanillic acid and 5-hydroxyindoleacetic acid 
were prepared in 50:50 methanol:deionized water. All stock standards were stored at -80°C. 
Working standards of dopamine, norepinephrine, serotonin (5-hydroxytryptophan), 3,4- 
dihydroxyphenylacetic acid, 5-hydroxyindoleacetic acid, and homovanillic acid were prepared 
at 20, 50, 100, 250, 500, 750, and 1000 ng/mL in elution solution. The internal standard, 3,4- 
dihydroxybenzylamine, was prepared at 100 ng/mL in elution solution. Working quality 
controls (QC) were prepared at 75, 300, and 600 ng/mL in elution solution. After preparation, 
the QC samples were stored and maintained at -80°C along with the study samples. Working 
standards of quinolinic acid, xanthurenic acid and nicotinic acid were prepared at 10, 25, 50, 
100, and 200 μg/mL in elution solution. Working quality controls (QC) were prepared at 30, 75, 
and 150 μg/mL in elution solution. After preparation, the QC samples were stored and 
maintained at -80°C along with the study samples. 
 
 
3.B.4. Sample Acquisition and Preparation 
Male wild-type C57BL/6J mice (10-13 weeks) were sacrificed and whole brains were 
removed and snap frozen in liquid nitrogen (average processing time ≤ 60 sec). Samples were 
stored at -80°C until subsequent analysis. For HPLC analysis, whole brains were weighed and 
then homogenized with 4 mL of elution solution in 10 mL polypropylene tubes (Eppendorf, 
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Westbury, NY, USA) using a PowerGen 125 homogenizer (Thermo Fisher Scientific, Fair 
Lawn, NJ, USA). Prior to homogenization, the internal standard, 3,4-dihydroxybenzylamine, 
was added to each tube of tissue sample. One mL of homogenate was transferred to a 1.5 mL 
conical plastic tube and centrifuged at 14,000 x g for 10 min in a refrigerated (4°C) centrifuge 
(Eppendorf 5810R, Westbury, NY, USA). The cleared supernatants (100 μL) were transferred 
to plastic autosampler microvials (Waters, Millford, MA, USA) and 5 μL was injected for 
HPLC analysis. 
 
 
3.C. RESULTS AND DISCUSSION 
 
3.C.1. Linearity, limits of detection and quantitation, computations 
 
The calibration curve was linear for dopamine, norepinephrine, serotonin, 3,4- 
dihydroxyphenylacetic acid, homovanillic acid, 5-hydroxyindoleacetic acid throughout the 
concentration range 20–1000 ng/mL with a mean correlation coefficient of ≥ 0.9993 
(unweighted normal linear regression, n = 10 analytical runs). The calibration curve was linear 
for quinolinic acid, xanthurenic acid, and nicotinic acid throughout the concentration range of 
10-200 µg/mL with a mean correlation coefficient of ≥ 0.9996. The LOD for dopamine, 
norepinephrine, 3,4-dihydroxyphenylacetic  acid,  and  homovanillic  acid  was  approximately 
5 ng/mL and for serotonin and 5-hydroxyindoleacetic acid was approximately 20 ng/mL (n = 3). 
The LOD for quinolinic acid, xanthurenic acid, and nicotinic acid was approximately 1 µg/mL 
and determined by evaluation of each analyte in elution solution (n = 3). The LOD was 
determined using dilutions of standard material and calculated (extrapolated) from each 
component’s standard curve (peak heights were greater than three times the standard deviation 
of the chromatographic baseline noise).  The lowest standard calibrator (i.e. 20 ng/mL and 10 
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μg/mL) was used as the lower limit of quantitation (LLOQ) and is administratively defined as a 
combined accuracy and precision within 30% of the nominal amount. The LOD and LLOQ 
were sufficient for measurement of endogenous concentrations of the neurotransmitters and 
metabolites in the majority of matrix samples. However, if a compound was found to be less 
than the LLOQ, it was reported as less than the LLOQ. For HPLC analysis, internal 
standardization and peak height response were used for all sample computations. 
Quantitation of kynurenic acid, an additional metabolite of the kynurenine pathway, also 
was attempted; however, using the current method, the UV detector did not provide sufficient 
sensitivity to detect kynurenic acid in the tissue matrix. This was confirmed by detectability of 
kynurenic acid in standard material and fortified tissue samples (data not shown). In addition, a 
voltammogram (+0.5 – +1.0 V) was constructed to evaluate electrochemical detection of 
kynurenic acid, but it remained undetectable in the tissue matrix (data not shown). 
 
 
3.C.2. Accuracy, precision and recovery 
 
The accuracy and precision for the method was determined by evaluation of replicate 
tissue samples at fortified analyte concentrations (Table 3.1). Brain tissue samples were divided 
into two post-homogenization aliquots, the first aliquot was treated as a blank while the second 
aliquot was fortified with 75, 300 or 600 ng/mL (n = 9 at each level) of dopamine, serotonin, 
norepinephrine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, 5-hydroxyindoleacetic acid 
and 30, 75, 150 μg/mL (n = 9 at each level) for quinolinic acid, nicotinic acid, and xanthurenic 
acid. The “blank” was then subtracted from the fortified sample to normalize for endogenous 
levels. The combined intra-day (within day) and inter-day (between day) accuracy of the 
method was reported as percent error of the measured concentration relative to the nominal 
concentration.  The combined intra-day and inter-day precision of the method was reported as 
53  
the percent relative standard deviation (% RSD). Using the sample preparation procedure 
described above, the method demonstrated sufficient accuracy and precision for all analytes 
(Table 3.1). 
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Table 3.1. Combined intra-day and inter-day accuracy and precision for all components 
 
Dopamine Norepinephrine Serotonin 
 
Conc.  %   %   %  
 Mean  % CV Mean  % CV Mean  % CV 
(ng/mL)  Error   Error   Error  
75 73 -3 4.8 64 -14 6.3 66 -12 4.6 
300 287 -4 1.3 288 -4 5.2 283 -6 2.3 
600 588 2 0.3 590 -2 0.4 583 -3 0.9 
 
 
3,4-Dihydroxyphenylacetic Homovanillic Acid 5-Hydroxyindoleacetic 
 
 Acid      Acid  
 
 
 
% CV 
Conc. 
(ng/mL) 
 
Mean 
% 
 
Error 
 
% CV 
 
Mean 
% 
 
Error 
 
% CV 
 
Mean 
% 
 
Error 
75 72 -4 8.4 70 -7 3.3 73 -3 4.9 
300 289 -4 1.6 285 -5 1.8 306 2 1.9 
600 594 1 0.9 587 -2 1.4 605 1 1.6 
 
 
Quinolinic Acid Nicotinic Acid Xanthurenic Acid 
 
Conc.  %   %   %  
 Mean  % CV Mean  % CV Mean  % CV 
(µg/mL)  Error   Error   Error  
30 29 -4 4.0 30 -1 5.1 29 -2 11 
75 74 -1 5.4 77 2 2.7 77 -2 1.5 
150 157 5 1.6 152 2 2.0 154 3 3.2 
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3.C.3. Stability 
 
The stability of all components in standard solution and brain tissue homogenate were 
evaluated at room temperature and at 4°C for 6 hours (short term stability-representing 
maximum run time). The tryptophan metabolites quinolinic acid, xanthurenic acid, and 
nicotinic acid standards were stable for 6 hours at room temperature and 4°C; however, these 
compounds were not stable at room temperature in brain homogenate over 6 hours possibly 
indicating metabolic processes. We found that using a 1:10 dilution of each sample with elution 
solution eliminated the matrix effect and provided stability of the tryptophan metabolites for 48 
hours at room temperature and 4°C. Short-term stability of monoamine neurotransmitters and 
metabolites in standard solution and brain tissue homogenate revealed that all analytes were 
stable at room temperature and 4°C for 6 hours. All stock standards and working standards 
were stable when stored frozen at -20°C for 30 days. This time span (30 days) frames the length 
of time samples were stored frozen during this study. Components were considered stable if the 
measured concentrations were within the inter-day QC acceptance range. 
 
 
3.C.4. Chromatography 
 
The method demonstrated good chromatographic selectivity without interferences from 
other constituents in the matrix at the retention times of each analyte (Figure 3.3).   A guard 
column (changed after ∼50 injections) was utilized to extend the analytical column lifetime as 
the method did not employ a formal sample cleanup step.  The analytical column was flushed 
 
after each analytical run using acetonitrile:deionized water (70:30, v/v). 
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Figure 3.3. Representative chromatograms demonstrating electrochemical detection of 
neurotransmitters and relative metabolites (norepinephrine, dopamine, serotonin, 3,4- 
dihydroxyphenylacetic acid, 5-hydroxyindoleacetic acid, and homovanillic acid) in (A) 
standard solution and (B) brain homogenate. Chromatograms (C) and (D) represent 
ultraviolet detection of tryptophan metabolites, quinolinic acid, nicotinic acid, and 
xanthurenic acid, in standard solution and brain homogenate, respectively. 
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3.D. CONCLUSIONS 
 
Recent in vitro evidence suggests a novel role for organic anion and cation transporters 
from the SLC22 family in the maintenance of CNS monoamine homeostasis [5-7]. In order to 
explore this possibility, particularly in SLC22 transporter knockout mouse models, a simple and 
efficient analytical assay capable of simultaneous detection of multiple monoamine NTs and 
their metabolites was required. Here, we reported a reliable HPLC-UV/ECD method for the 
evaluation of several neurotransmitters (dopamine, norepinephrine, serotonin (5- 
hydroxytryptophan)) and their relative metabolites (3,4-dihydroxyphenylacetic acid, 
homovanillic acid, 5-hydroxyindoleacetic acid, quinolinic acid, xanthurenic acid, and nicotinic 
acid) in mouse brain homogenate. This method provided sufficient selectivity and sensitivity 
for quantitation of these endogenous components in the matrix. The method employed a simple 
sample preparation for tissue with the use of an internal standard (3,4-dihydroxybenzylamine) to 
provide information regarding analyte recovery. In the future, this assay will be applied to 
assess changes in CNS monoamine balance in transporter knockout mouse models. 
58  
 
 
CHAPTER 4 
 
 
 
 
ORGANIC ANION TRANSPORTERS 1 (OAT1) AND OAT3 IN THE MURINE 
CHOROID PLEXUS: A POTENTIAL MECHANISM FOR MAINTAINING 
ENDOGENOUS MONOAMINE HOMEOSTASIS IN THE CENTRAL NERVOUS 
SYSTEM 
 
Drawn from manuscript submitted for publication in Physiology and Behavior, 2014 
 
 
 
 
 
4.A. INTRODUCTION 
 
According to a recent assessment by the World Health Organization, mental disorders 
represent the leading cause of disability in the US and generate ~58 billion dollars in medical 
costs each year (NIMH; WHO, 2008). Annually, among the US population 18 years and older, 
~40 million individuals suffer from an anxiety disorder, of which ~2 million exhibit obsessive- 
compulsive disorder (OCD), and ~14 million experience a major depressive disorder (Kessler et 
al., 2005; WHO, 2008). The association between CNS levels of biogenic amines (i.e. dopamine, 
serotonin, norepinephrine) and the persistence of these neurobehavioral conditions has been 
studied for almost 50 years with little improvement in diagnosis and clinical outcomes. Thus, a 
more complete understanding of the underlying mechanisms regulating CNS monoamine levels 
may provide new insight to the pathways impacting normal CNS monoamine homeostasis 
and/or pharmacological action of current medications, potentially leading to new therapeutic 
approaches to normalizing monoaminergic neurotransmission, resulting in improved treatment 
and reduced health care costs. 
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One aspect of CNS regulation of monoaminergic neurotransmission involves pathways 
targeted toward the efficient removal of released neurotransmitters (NTs), so-called uptake 1 
and uptake 2 transport systems. Neuronal uptake 1 activity is comprised of the high affinity, 
low capacity monoamine transporters for dopamine (DAT), serotonin (SERT), and 
norepinephrine (NET), which function to ensure rapid reuptake of released NTs by the pre- 
synaptic neuron. A second, non-neuronal low affinity, high capacity transport system, uptake 2, 
functions to clear NTs, as well as their degradative metabolites that have diffused away from the 
synaptic terminal region. The precise nature and role of the uptake 2 pathway in 
monoaminergic signaling and homeostasis is poorly understood. However, a variety of recent 
studies comprising pharmacological profiles, mRNA expression, immunohistochemistry, and 
gene knockdown and knockout have provided evidence suggesting that members of the organic 
cation/anion/zwitterion transporter family (SLC22) represent a previously unrecognized 
component of the uptake 2 clearance pathway (Pritchard et al., 1999; Sweet et al., 2001; Ohtsuki 
et al., 2002; Sweet et al., 2002; Sykes et al., 2004; Kitaichi et al., 2005; Vialou et al., 2008; 
Wultsch et al., 2009). 
The Solute Carrier (SLC) superfamily of transporters contains approximately 370 
identified transport proteins divided into 48 families. Neuronal uptake 1 transporters, DAT, 
SERT, and NET, are members of SLC6, the sodium and chloride dependent neurotransmitter 
transporter family. The SLC22 family contains 25 members subdivided into three subgroups: 
organic cation transporters (OCTs), organic anion transporters (OATs), and organic 
cation/carnitine transporters (OCTNs) (Sweet, 2005; Sweet, 2010; VanWert et al., 2010). The 
first member of the OAT subfamily, Oat1, was isolated from rat kidney (Sweet et al., 1997). 
Subsequently, ten additional OATs have been cloned and partially characterized: Oat2-10 and 
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Urat1 (VanWert et al., 2010). Active renal excretory transport mediated by OATs is a major 
determinant of the effects of many therapeutics and toxic chemicals (Cihlar et al., 1999; Mulato 
et al., 2000). In addition to the kidney, active OA transport is an important function of other 
barrier epithelia. For example, the composition of the extracellular fluid of the brain is tightly 
regulated and highly insulated from changes in the circulation. This regulation is mediated by 
the blood-brain and the blood-cerebrospinal fluid barriers, the latter of which is comprised of the 
choroid plexus (CP), arachnoid membrane, and circumventricular organs (Segal, 1998; Pritchard 
et al., 1999). The cells of these epithelia form tight junctions, which slow the penetration of 
solutes, drugs, and other foreign chemicals into the brain and limit the passive efflux of 
endogenous compounds (i.e. monoaminergic NTs and their metabolites) from the brain(Segal, 
1998; Pritchard et al., 1999). Thus, the CP protects the CNS against toxicity by effectively 
removing environmental pollutants, therapeutic drugs, and waste products of CNS metabolism 
from the cerebrospinal fluid (CSF) (Forn, 1972; Pritchard, 1980; Suzuki et al., 1987). Because 
the characteristics of OA transport by the CP are similar to that in kidney, it was hypothesized 
that the same transporters identified in the kidney could be responsible for mediating OA uptake 
in CP (Pritchard et al., 1999). Subsequently, Oat1 and Oat3 mRNA expression was detected in 
adult rat and murine CP (Sweet et al., 2002). For Oat1 and Oat3 expressed in CP to participate 
in OA removal from CSF to blood, they would have to be targeted to the apical membrane of 
the CP. In support of this, localization of an Oat1/green fluorescent protein fusion construct 
(Oat1-GFP) was observed in the apical membrane in intact rat CP transfected in vitro (Pritchard 
et al., 1999). Further, substantial accumulation of the OA fluorescein was observed in the cells 
and underlying capillaries of CP from wildtype (WT) mice, whereas, CP of Oat3 knockout 
(Oat3-/-) mice exhibited a significant decrease in fluorescein uptake (Sweet et al., 2002).  This 
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suggests that, like Oat1, Oat3 is targeted to the apical membrane in CP and involved in OA 
transport from CSF to blood. Therefore, Oat1 and Oat3 are poised to play an active role in the 
removal of NTs and their metabolites from CSF and in protection of the CNS from toxic injury. 
Normal brain function can be disturbed by improper clearance of monoamine NTs and 
their metabolites (Sullivan et al., 1978; Giroud et al., 1990). Several acidic metabolites of the 
monoamine NTs dopamine (DA), serotonin (5-HT), and norepinephrine (NE) are known 
substrates, or inhibitors, of Oat1 and Oat3; including 5-hydroxyindole-3-acetic acid (5-HIAA), 
4-hydroxy-3-methoxyphenylacetic acid (homovanillic acid; HVA), 5-methoxy-3-indoleacetic 
acid, 3,4-dihydroxyphenylacetic acid (DOPAC), 3-methoxy-4-hydroxymandelic acid, 4- 
hydroxy-3-methoxymandelic acid, and 5-methoxytryptophol (Kusuhara et al., 1999; Sekine et 
al., 2000; Ohtsuki et al., 2002). Furthermore, peripheral administration of probenecid (a potent 
inhibitor of OATs) results in increased HVA and 5-HIAA levels in the CSF (Forn, 1972; 
Emanuelsson et al., 1987a; Emanuelsson et al., 1987b). Thus, changes in expression and 
function of Oat1 and Oat3 in CP may play a previously unrecognized role in CNS 
monoaminergic homeostasis and they may represent unexplored contributors to behavioral 
states associated with monoamine imbalance in the CNS. 
In the current series of investigations, we studied basal motor behavior, and anxiety-like 
and depressive-like behaviors in Oat1 and Oat3 knockout mice compared with age-matched WT 
mice bred in-house. We then assessed monoamine homeostasis by measuring tissue levels of 
neurotransmitters (DA, NE, 5-HT) and relevant metabolites (DOPAC, HVA, 5-HIAA, QA, NA, 
and XA) using high performance liquid chromatography methodology. Together, the findings 
of the current study extend the behavioral and biochemical phenotypes of Oat knockout mice, as 
these mice displayed a significant age-dependent change in a measure of anxiety-like behavior 
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without concomitant changes in their basal motor behavior. Further,  the  current  findings 
include previously unknown correlative changes in neurotransmitter and relevant metabolite 
concentrations in aged mice. 
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4.B. METHODS 
 
4.B.1. Subjects 
 
Male and female wild-type (WT), Oat1 knockout (Oat1-/-), and Oat3 knockout (Oat3-/-) 
mice of C57Bl6J background were bred and housed in university animal facilities until they 
reached specific ages of interest: 3, 6, 9, 12, 15, or 18 mo. Sample size and mean weight for 
each group are listed in Table 4.1. Subjects were housed in groups of 2 to 5 to avoid the possible 
confounding effects of isolation or over-crowding. Subjects had ad libitum access to food and 
water, and were maintained under 12/12 hour light/dark cycle. All behavioral assessments were 
conducted during the light phase of the cycle. 
Animal use and care procedures were in accordance with the National Institutes of 
Health Guidelines for the Care and Use of Laboratory Animals and were approved by the 
Institutional Animal Care and Use Committee of Virginia Commonwealth University. 
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Table 4.1. Strain sample size (n) and mean weight (g). 
 
 
 
 
Gender Age  n  Mean Weight (g) ± SEM 
 (mo) WT Oat1-/- Oat3-/- WT Oat1-/- Oat3-/- 
Female 3 9 9 6 20 ± 1 20 ± 1 20 ± 1 
 6 7 10 6 21 ± 1 21 ± 2 23 ± 2 
 9 8 6 6 22 ± 1 23 ± 1 25 ± 1 
 12 7 7 6 22 ± 1 25 ± 1 26 ± 1 
 15 2 8 6 25 ± 1 24 ± 1 27 ± 1 
 18 7 10 2 26 ± 1 26 ± 1 27 ± 2 
Male 3 7 9 6 26 ± 2 26 ± 1 25 ± 1 
 6 6 10 6 27 ± 2 29 ± 1 26 ± 1 
 9 12 6 10 27 ± 1 30 ± 2 30 ± 1 
 12 6 7 6 29 ± 2 31 ± 1 30 ± 2 
 15 2 10 6 30 ± 1 35 ± 4 37 ± 1 
 18 9 9 2 32 ± 3 33 ± 2 38 ± 2 
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4.B.2. Behavioral Tests 
 
All subjects were weighed and handled daily for 5 days prior to the start of behavioral 
assessments to minimize stress-induced handling artifacts. Each animal was assessed in all of 
the following procedures: open field activity (OFA), light dark exploration (LD), marble 
burying (MB), and tail suspension test (TST). Animals were randomly assigned to one of the 
three sequences to eliminate any potential test order bias with a minimum of 3 consecutive days 
between assessments in the individual paradigms (Figure 4.1). OFA and LD procedures were 
monitored and recorded with high sensitivity Fire-I firewire cameras (UniBrain Fire-I, San 
Ramon, CA) suspended above the apparatus and interfaced to AnyMaze software (Stoelting, 
Wood Dale, IL). The TST was performed at the end of all sequences due to the stress and 
potentially lasting deficits in motivation induced by this assessment. Prior to the start of any 
assessment, the mice were allowed to acclimate to the test room for one hour. Following 
completion of a testing sequence, mice were sacrificed using cervical dislocation and whole 
brains removed, snapped frozen using liquid nitrogen (<2 min from time of dislocation to snap 
frozen), and stored at -80°C until further analysis. 
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Figure 4.1. Schematic depicting the behavioral assay regimen for each sequence. Animals 
were randomly assigned to one of the three sequences to eliminate any potential test order bias 
with a minimum of three consecutive days between assessments in the individual paradigms. 
The TST was performed at the end in all sequences due to the stress and potentially lasting 
deficits in motivation. 
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4.B.2.1. Open Field Activity 
 
 
Animals were tested for a 30 minute trial on 3 consecutive days. The OFA chambers 
consisted of 41 cm x 41 cm x 46 cm acrylic cubicles. The center zone was defined as a 20 x 20 
cm square in the center of the chamber. Mice were then placed in the center zone of the 
chamber. Total distance traveled and total time mobile were used as indices of basal motor 
activity. Total time spent in the center zone and the numbers of entries to the center zone were 
used as indices to determine the degree of thigmotaxis. Mice were evaluated daily for 3 
consecutive days in order to determine baseline behavior in a novel environment and habituation 
to a novel environment. Each subject was tested at the same time each day; however, time of 
day was randomized across the subjects in each group. 
4.B.2.2. Light Dark Exploration 
 
 
The procedure utilized was based on a previously published study (Bourin and Hascoet, 
2003). Animals were tested for a single 30 minute trial. The LD chambers consisted of a single 
experimental chamber (42 cm x 42 cm x 30 cm) with an enclosed black acrylic box insert (41 
cm x 21 cm x 30 cm). There was a small opening (7 cm x 5 cm) present in the base of the black 
box permitting movement between the light and dark zones. The light zone was comprised of 
the remainder of the experimental chamber (41 cm x 21 cm x 30 cm) with white walls. 
Suspended 45 cm above the light zone was a 100 W lamp. Animals were placed in the light 
zone near the dark zone entrance. Total time spent in the light zone and the numbers of entries 
into the light zone were scored as indices of anxiety-like behavior using AnyMaze software. 
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4.B.2.3. Marble Burying 
 
 
The MB procedure was based on previously published studies (Deacon, 2006; Thomas et 
al., 2009). Animals were tested for a single 20 minute trial. The testing apparatus consisted of a 
polycarbonate cage (20 cm x 30 cm x 19 cm) filled to a depth of 5 cm with wood chip bedding 
(Harlan Sani-Chip, Indianapolis, IN). Marbles (n = 20 blue glass) were evenly spaced in a 4 x 5 
grid across the surface of the bedding. Individual mice were placed into the center of the 
apparatus and left undisturbed in visual and acoustic isolation for 20 min. At the end of the 
assessment, the mice were removed and the number of marbles buried was manually scored. 
Marbles buried was defined as ≥ 67% of the marble covered by bedding. 
4.B.2.4. Tail Suspension Test 
 
 
The TST procedure used was based on that described by Steru et al. (1985) with 
modifications by Yoshikawa et al. (2002) (Steru et al., 1985; Yoshikawa et al., 2002). The 
apparatus consisted of a 40 cm X 3 cm X 0.5 cm acrylic bar fixed horizontally 40 cm above the 
laboratory bench providing a smooth flat surface on which to affix the mouse tail. Testing was 
performed in both acoustic and visual isolation from other subjects. During testing, the mouse 
was attached to the bar by medical adhesive tape placed approximately 1 cm from the tip of its 
tail, suspended in an inverted position above a foam pad placed on the bench top. Total time 
immobile was scored manually over a 6 min assessment. Immobility was defined as the 
absence of any limb or body movements, except for those caused by respiration. 
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4.B.3. Analysis of Monoamines and Relative Metabolites 
 
 
A high performance liquid chromatography (HPLC) method utilizing electrochemical 
detection (ECD) for the determination of serotonin (5-hydroxytryptamine, 5-HT), dopamine 
(DA), norepinephrine (NE), homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), 
3,4-dihydroxyphenylacetic acid (DOPAC), and utilizing ultraviolet (UV) detection for the 
determination of nicotinic acid (NA), quinolinic acid (QA), and xanthurenic acid (4, 8- 
dihydroxyquinoline-2-carboxylic acid, XA) in whole brain was developed (Farthing et  al., 
2014). An internal standard, 3,4-dihydroxybenzylamine (DHBA), was used to account for any 
loss in analyte due to sample preparation. Brain tissue samples were prepared for HPLC 
analysis by homogenization in an aqueous solution (deionized water with 1.0% acetic acid and 
0.5% phosphoric acid, pH 3.0), followed by centrifugation at 10,000 x g for 10 min (6°C). 
Resultant supernatants were transferred to plastic HPLC autosampler vials (Waters®, Milford 
MA, USA) with 5μL injected into the HPLC for analysis. For analysis of QA, NA, and XA, a 
1:10 dilution of the supernatants was made to reduce metabolic matrix effects. The HPLC 
equipment consisted of an Agilent 1200 series degasser (Model G1322A), solvent delivery 
system (quaternary) (Model G1311A), autosampler (Model G1329A), thermostatted column 
compartment (Model G1316A), variable wavelength detector (Model G1314D) (Agilent 
Technologies, Santa Clara, CA, USA), and a Coulochem III electrochemical detector (Thermo 
Fisher Scientific (ESA, Inc), Fair Lawn, NJ, USA). The analytical column used was an HR-80 
C18 (80 mm x 4.6 mm I.D; Thermo Fisher Scientific, Fair Lawn, NJ, USA) coupled to a C18 
guard column (12.5 mm x 4.6 mm I.D.; Phenomenex®, Torrance, CA, USA). The mobile phase 
consisted of 75 mM sodium dihydrogen phosphate (monohydrate), 1.7 mM 1-octanesulfonic 
acid sodium salt, 25 µM EDTA, 10% acetonitrile, 1% triethylamine with a final pH of 3.0 
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adjusted using concentrated H3PO4 (prepared using Thermo Fisher Scientific (ESA, Inc.) 
recommendations for catecholamine analysis), and used at a flow rate of 1.0 mL/min. An 
injection volume of 5 µL of the prepared tissue homogenate sample was accomplished using the 
Agilent 1200 series Model G1329A autosampler. Component detection was achieved using 
ESA, Inc. Coulochem III Electrochemical Detector with a voltage setpoint of 600 mV for DA, 
5-HT, NE, DOPAC, HVA, and 5-HIAA. The voltage setpoint was established by conducting a 
voltammogram for all components and determining the voltage at which responses were 
optimal. Component detection was achieved for QA, NA, and XA at an UV absorbance 
wavelength of 260 nm. Data acquisition and component computations were performed using 
ChemStation™ software (Agilent Technologies, Santa Clara, CA, USA). 
 
 
4.B.4. Statistical Analyses 
 
 
One-way and two-way analyses of variance (ANOVA) were used as appropriate. One- 
way ANOVA was used to investigate comparisons within genotype where the independent 
variable was age. Two-way ANOVA was used to investigate comparisons across genotypes 
where the independent variables were genotype and age. Two-way ANOVA was also used to 
investigate gender specific comparisons within a genotype where the independent variables 
were gender and age. Post-hoc comparisons were conducted using Bonferroni pairwise 
comparisons.  The α level for statistical significance was p < 0.05. 
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4.C. RESULTS AND DISCUSSION 
 
 
4.C.1. Open Field Activity 
 
WT, Oat1-/- and Oat3-/- mice exhibited similar total time mobile (Figure 4.2) and total 
distance traveled (data not shown) at all age. Additionally, this value remained consistent 
regardless of age or genotype demonstrating that these parameters had no effect on baseline 
motor behavior [F(10,220) = 1.02, p = 0.4]. In fact, there were no significant differences in the 
total time mobile when comparing Day 2 vs. Day 3 at any given age or within genotype across 
age (data not shown). When habituation to a novel environment was evaluated by comparing 
total time mobile on Day 1 vs. total time mobile on Day 2, no significant differences in 
habituation patterns across genotypes at any given age or within genotype across age were 
identified (data not shown). There were no significant differences among groups in the time 
spent in the center zone or the number of center zone entries (data not shown). 
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Figure 4.2. Total time mobile (mean ± SEM) in an open field for WT, Oat1-/-, and Oat3-/- 
mice across age. Mice of all three genotypes exhibited similar total time mobile indicating 
basal motor activity was not significantly different across genotype or age. Data are from male 
and female animals, see Table 4.1 for group details. 
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4.C.2. Light Dark Exploration 
 
The number of transitions between the dark and lighted compartments and the time spent 
in the light zone are measures of anxiety-like behavior. There were no statistically significant 
differences in the number of transitions or the time spent in the light compartment. 
 
 
4.C.3. Marble Burying 
 
No significant differences in the number of marbles buried were observed within or 
across (WT vs. Oat1-/-, WT vs. Oat3-/-, Oat1-/- vs. Oat3-/-) genotypes from 3 to 12 mo of age 
(Figure 4.3). However, at 15 and 18 mo of age, both Oat1-/- and Oat3-/- animals exhibited a 
sudden and significant reduction in the number of marbles buried vs age-matched WT control 
animals [F(10,220) = 12.56), p<0.0001]. The number of marbles buried by WT mice remained 
consistent from 3 to 18 mo of age (Figure 4.3). The decrease in burying behavior at 15 and 18 
mo observed in Oat1-/- and Oat3-/- animals was significant compared to Oat1-/- and Oat3-/- 
animals 3 to 12 mo of age, respectively. 
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Figure 4.3. The number of marbles buried (mean ± SEM) by WT, Oat1-/-, and Oat3-/- mice 
across age. Oat1-/- and Oat3-/- mice almost completely eliminated burying behavior at 15 and 18 
mo of age. aP < 0.001 compared to WT 15 mo, bP < 0.001 compared to WT 18 mo, cP < 0.001 
compared to Oat1-/- at 3, 6, 9 and 12 mo., dP < 0.001 compared to Oat3-/- at 3, 6, 9 and 12 mo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a,c 
a,d 
b,c 
b,d 
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4.C.4. 4. Tail Suspension Test 
 
 
Three mice (33%) in the 3 mo WT group failed to provide valid data in the tail 
suspension test because they repeatedly climbed their tails. This behavior has been previously 
reported as prevalent among mice of C57Bl/6 background between 8-10 weeks of age [Dalvi 
1999, Mayorga 2001]. Interestingly, we had no mice successfully climb their tails in either of 
the Oat deficient genotypes at 3 mo of age. 
The mean time spent immobile (seconds) for each of the genotypes across age is shown 
in Figure 4.4. As can be seen, genotype and age had a significant interaction effect on the mean 
time spent immobile particularly from 3 to 9 mo of age [F(10,220) = 3.06), p = 0.001]. Post-hoc 
comparisons revealed that 3 and 9 mo Oat1-/- mice spent significantly less time immobile than 
similarly aged WT control animals; and a similar trend was observed at 6 mo, but this difference 
did no reach significance. Oat1-/- mice exhibited a significant increase in total time spent 
immobiles (vs. 9 mo) from 12 to 18 mo of age, to a level similar to that for WT animals. Oat3-/- 
animals were similar to WT at 3 mo of age; however, at 6 and 9 mo, they also exhibited a 
significant decrease in total time immobile vs. WT (Figure 4.4). Immobility time at 12 and 18 
mo was similar between WT and Oat3-/- mice; however, unlike Oat1-/- animals, Oat3-/- total time 
immobile was significantly reduced vs WT at 15 mo. Like Oat1-/- mice, Oat3-/- animals also 
demonstrated a significant decrease in total time immobile from 12 to 18 mo of age vs. Oat3-/- at 
9 mo. Except for the 3 mo Oat3-/- animals, Oat1-/- amd Oat3-/- mice showed similar activity 
patterns in the TST. 
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Figure 4.4. Tail suspension test revealed a significant genotype and age interaction effect 
on the mean time spent immobile. Oat-/- mice tended to display decreased immobility at 
younger ages (i.e. 3, 6 and 9 mo) compared to age matched WT and themselves at older ages 
(i.e. 12, 15 and 18 mo). aP<0.05 compared to 3 mo WT, bP<0.05 compared to 6 mo WT, 
cP <0.01 compared to 9 mo WT, dP<0.05 compared to 15 mo WT, eP<0.05 compared to Oat1-/- 
at 12, 15 and 18 mo, fP<0.05 compared to Oat3-/- at 12, 15 and 18 mo. 
 
 
 
 
 
 
 
 
 
 
 
d 
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There were no gender specific differences across ages within the WT or Oat1-/- mice. In 
stark contrast, Oat3-/- mice displayed a significant gender and age interaction effect on the mean 
time spent immobile [F(5,56 = 3.7, p = 0.006] (Figure 4.5). Post-hoc comparisons revealed that 
Oat3-/- females spent significantly less time immobile compared to their males counterparts at 
ages 3, 12, 15 and 18 mo (p≤0.05). 
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Figure 4.5. Tail suspension test data for Oat3-/- mice parsed by gender. TST data revealed a 
significant gender and age interaction effect on the mean time spent immobile. Female Oat3-/- 
mice spent less time immobile compared to age matched Oat3-/- males at 3, 12, 15 and 18 mo. aP 
< 0.05, bP<0.01, and cP<0.001 compared to age matched counterpart. 
 
 
 
 
 
 
 
a a c b 
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4.C.5. Whole brain concentrations of monoamines and relevant metabolites 
 
 
 
Table 4.2 lists the mean concentrations of monoamine neurotransmitters (5-HT, DA, and 
NE) and relevant metabolites (HVA, 5-HIAA, DOPAC, QA, NA and XA) for each 
experimental group. Genotype and age had a significant interaction effect on the mean 
concentrations of several of the monoamine neurotransmitters and their relative metabolites. 
Post-hoc comparisons revealed that tissue levels of DA in Oat1-/- and Oat3-/- mice at 12, 15 and 
18 mo of age were significantly decreased compared to age matched WT (p<0.05). Similarly, 
concentrations of the DA metabolites, DOPAC and HVA were significantly lower in aged Oat-/- 
mice (12, 15 and 18 mo) compared to age-matched WT mice (p<0.05). Tissue levels of NE in 
Oat1-/- and Oat3-/- mice at any given age were not significantly different compared to age 
matched WT. Interestingly, post-hoc comparisons also revealed that mean tissue concentrations 
of 5-HT were significantly decreased in WT at 12, 15 and 18 mo of age compared to age 
matched Oat1-/- and Oat3-/- mice (p<0.05). There was an age related decline in WT mice that 
was absent across all ages in OAT knockout mice. There was no significant change in mean 
concentrations of 5-HIAA across genotypes at any given age. 
 
 
One-way ANOVA indicated that the mean concentrations of DA and NE were not 
significantly different in WT mice across age; however, there was a trend observed for an age 
dependent decrease in NE concentrations in WT mice (p = 0.06). This analysis also revealed a 
significant difference within the Oat1-/- and Oat3-/- mice across age (p<0.01). The mean 
concentrations of DA and NE at 12, 15 and 18 mo of age in Oat1-/- were significantly lower than 
concentrations at 3 through 9 mo of age in Oat1-/- mice (p<0.01). A significant decrease in 
mean DA and NE concentrations in aged mice was also observed within the Oat3-/-  genotype 
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(p<0.01). Similarly, the mean concentrations of DOPAC at 12, 15 and 18 mo of age in Oat1-/- 
was significantly lower than concentrations at 3 through 9 mo of age in Oat1-/- mice (p<0.01). 
A significant decrease in mean DOPAC concentrations in aged mice was also observed within 
the Oat3-/- genotype (p<0.01). HVA concentrations at 12, 15 and 18 mo of age was also 
significantly lower compared to ages 3 through 9 mo within both Oat1-/- and Oat3-/- knockout 
strains. In stark contrast, mean 5-HT concentrations were relatively unchanged in both Oat1-/- 
and Oat3-/- mice across age, but were found to be significantly decreased within WT across age 
(p<0.01). Concentrations of 5-HT in 12, 15 and 18 mo WT mice were significantly less than 
mean concentrations observed in WT mice from 3 through 6 mo of age (p< 0.05). There was no 
significant change in mean concentrations of 5-HIAA within genotypes across age. 
 
 
Lastly, the kynurenine metabolites, QA, NA, and XA, were evaluated in 3, 12 and 18 mo 
old mice for all three genotypes (Table 4.3). No differences in the mean concentrations of these 
metabolites either across genotype at any given age or within genotype across age were 
detected. 
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Table 4.2. Monoamine neurotransmitter and metabolite concentrations in whole brain in 
WT, Oat1-/-, and Oat3-/- across age. 
 
 
 
Mean Conc. [ng/mg] ± SEM 
Genotype Age 
(mo) 
DA NE 5HT DOPAC HVA 5-HIAA 
WT 3 5.5 ± 1.2 4.7 ± 1.2 4.1 ± 0.8 0.5 ± 0.02 0.3 ± 0.04 0.5 ± 0.06 
 6 5.3 ± 0.7 4.6 ± 0.9 4.4 ± 1.2 0.7 ± 0.06 0.5 ± 0.09 0.7 ± 0.l 
 9 4.7 ± 1.0 4.2 ± 1.4 4.0 ± 0.5 0.5 ± 0.09 0.4 ± 0.06 0.6 ± 0.04 
 12 4.6 ± 0.5 4.3 ± 1.4 2.2 ± 0.4 0.5 ± 0.04 0.8 ± 0.06 0.5 ± 0.04 
 15 4.0 ±0.4 3.9 ± 0.3 2.1 ± 0.6 0.5 ± 0.06 0.6 ± 0.02 0.6± 0.06 
 18 5.4 ± 1.1 3.7 ± 0.8 2.4 ± 0.2 0.6 ± 0.04 0.6 ± 0.08 0.4 ± 0.1 
Oat1KO 3 5.7 ± 1.0 5.2 ± 1.7 4.6 ± 0.8 0.8 ± 0.05 0.8 ± 0.06 0.5 ± 0.05 
 6 4.8 ± 0.7 5.1 ± 0.8 4.3 ± 0.8 0.6 ± 0.04 0.8 ± 0.02 0.5 ± 0.03 
 9 4.5 ± 0.6 4.6 ± 0.4 3.9 ± 0.8 0.7 ± 0.08 0.6 ± 0.01 0.6 ± 0.02 
 12 3.0 ± 0.4 3.0 ± 0.5 3.8 ± 1.1 0.4 ± 0.09 0.2 ± 0.06 0.7 ± 0.08 
 15 2.8 ± 0.3 2.7 ± 1.0 4.3 ± 0.8 0.4 ± 0.03 0.4 ± 0.06 0.6 ± 0.05 
 18 3.2 ± 0.5 3.0 ± 0.6 3.1 ± 0.5 0.3 ± 0.04 0.4 ± 0.05 0.5 ± 0.05 
Oat3KO 3 5.4 ± 0.4 4.8 ± 0.8 3.5 ± 1.0 0.7 ± 0.06 0.5 ± 0.05 0.6 ± 0.05 
 6 5.2 ± 0.9 6.3± 1.3 3.9 ± 1.2 0.8 ± 0.05 0.6 ± 0.05 0.6 ± 0.07 
 9 4.6 ± 0.5 4.2 ± 0.6 3.7 ± 1.1 0.6 ± 0.02 0.6 ± 0.06 0.5 ± 0.04 
 12 2.9 ± 0.8 2.5 ± 0.3 3.7 ± 0.4 0.4 ± 0.07 0.3 ± 0.09 0.7 ± 0.04 
 15 2.7 ± 0.5 3.0 ± 0.5 4.0 ± 0.5 0.3 ± 0.02 0.4 ± 0.04 0.5 ± 0.08 
 18 3.0 ± 1.0 2.1 ± 0.6 3.6 ± 0.7 0.3 ± 0.05 0.3 ± 0.06 0.6 ± 0.05 
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Table 4.3. Kynurenine pathway metabolite concentrations in whole brain in WT, Oat1-/-, 
and Oat3-/- at 3, 12, and 18 mo of age. 
 
 
 
Mean Conc. [µg/g] ± SEM 
Genotype Age 
(mo) 
QA NA XA 
WT 3 28.8 ± 4.2 26.7 ± 3.5 15.4 ± 2.4 
 12 32.4 ± 6.5 23.5 ± 5.9 13.2 ± 3.2 
 18 33.2 ± 5.1 23.8 ± 5.2 12.6 ± 4.2 
Oat1KO 3 27.6 ± 9.0 25.4 ± 3.4 12.6 ± 4.8 
 12 24.9 ± 4.8 26.5 ± 2.8 13.5 ± 3.4 
 18 23.9 ± 5.1 25.7 ± 4.1 14.0 ± 2.5 
Oat3KO 3 24.6 ± 26 25.8 ± 3.6 16.2 ± 4.5 
 12 26.5 ± 6.3 27.3 ± 4.4 14.7 ± 5.5 
 18 30.2 ± 10.0 31.9 ± 8.2 13.7 ± 4.4 
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4.D. DISSCUSION 
 
The aim of the present study was to evaluate neurochemical and behavioral effects 
associated with loss of Oat1 or Oat3. Four behavioral paradigms were used to provide 
information on basal motor behavior, and anxiety-like and depressive-like behaviors across 6 
age points from 3 mo to 18 mo in WT and OAT knockout mice bred and housed under the same 
conditions. Following the behavioral assessments, concentrations of neurotransmitters and their 
respective metabolites were determined using HPLC methodology. Our studies provide the first 
evidence of the significant effects of OAT transporter deletion on multiple measures of anxiety- 
like/depressive-like behaviors and concentrations of monoamine neurotransmitters and their 
metabolites in whole brain. 
 
 
The OFA paradigm is a classical test of exploratory locomotor behavior that provides a 
measure of basal activity and thus is an essential component of behavioral phenotyping. In 
addition, patterns of activity within the field can be determined providing additional information 
about novel strains. In open fields, animals that spend more time in the periphery of the field 
(thigmotaxis) are said to display a more anxious-like phenotype than those that freely explore 
the center of the field (Prut and Belzung, 2003). Additionally, generalized locomotor 
hyperactivity may reflect environmental neophobia (an increased fear of novel environments). 
In the current study, the total time spent mobile and the total distance traveled in the OFA 
paradigm were parameters used to measure basal motor activity across genotype at any given 
age. There were no significant differences in these measures across age for each of  the 
genotypes or across genotype at any given age (as seen in Figure 1, and data not shown). In 
addition, when parsed by gender, there were no gender-specific effects on basal motor function. 
Therefore, any alterations observed in anxiety-like or depressive-like behaviors in the additional 
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paradigms are not simply reflective of genotype or aged-related differences in basal motor 
activity. Similarly, there were no significant differences in thigmotactic behavior observed 
when comparing the distance traveled in the center zone and time in the center zone as a percent 
of the total distance traveled and total time mobile in the field across strain by age, genotype, or 
gender. Finally, when we evaluated habituation to a novel environment by comparing total 
distance traveled and total time mobile in the field on Day 1 vs. Day 2, we found that there were 
no significant differences across age for any of the genotypes, or across genotype at any given 
age, in habituation patterns. 
 
 
Marble burying has been suggested as a model to measure anxiety-like behaviors, 
specifically compulsive behaviors, and as a possible model of obsessive compulsive disorder in 
rodents (Thomas et al., 2009; Albelda and Joel, 2012). The effects of OAT deletion were most 
profound in the MB procedure where Oat1-/- and Oat3-/- mice almost completely ceased burying 
behavior at 15 and 18 mo of age. These findings may suggest decreased compulsive-like 
behavior in the aged OAT knockout mice. Because results from the OFA (Figure 1) failed to 
demonstrate any significant differences in the total time spent mobile or the total distance 
traveled in the field, the MB results do not simply reflect lower basal activity levels, but appear 
to demonstrate true differences in burying behavior. The pattern of anxiolytic effect seen in our 
aged knockout mice is similar to what has been observed in serotonin transporter (SERT) and 
dopamine transporter (DAT) knockout mice when studied in the MB procedure (Line et al., 
2011; Pang et al., 2011; Fox et al., 2013). However, it has been proposed that the decrease in 
burying behavior observed in DAT knockout mice was a result of hyperactivity and disinterest 
in the marbles noted during the MB procedure (by personal observation; Fox et al., 2013).  In 
marked contrast to the locomotor observations in DAT KO mice during the MB procedure, no 
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differences in locomotor activity during the MB procedure was observed in either knockout 
strain across all ages. It should be noted that throughout the 30 min test, the mice were active, 
but at 15 and 18 mo the Oat-/- and Oat3-/- animals essentially maneuvered around the cage 
without disturbing the marbles (personal observation). 
 
 
It was generally hypothesized that due to similarities in both function and location of the 
Oat1 and Oat3 transporters, behavioral and neurochemical alterations would be similar between 
the two genotypes across age. In the paradigms measuring anxiety-like behavior, this 
hypothesis remains true with the Oat1-/- and Oat3-/- strains providing similar behavioral 
alterations; however, in the TST paradigm measuring depression-like behavior, the genetic 
background of OAT deficient mice displayed some differences. When comparing the TST data 
in the knockout strains to each other at each age, the point where they significantly deviated 
from each other was at 3 mo of age. As demonstrated in Figure 4.4, genotype and age had a 
significant impact on the mean time spent immobile with 3 mo Oat1-/- mice spending 
significantly less time immobile than Oat3-/- and WT mice at 3 mo. When comparing the 
knockout genotypes relative to WT at each time point, there were differences at varying ages 
with an overall trend of knockout mice spending less time immobile compared to WT. The 
Oat1-/- mice spent significantly less time immobile compared to age-matched WT at 3 and 9 mo 
of age, while the 6 mo Oat1-/- mice tended to also spent less time immobile than WT. Oat3-/- 
mice spent significantly less time immobile compared to age-matched WT at 6 and 9 mo of age. 
Perhaps, the inconsistencies in this measure of depressive-like behavior can be partly explained 
by the observed gender-specific variations in mean time spent immobile found only within the 
Oat3-/- strain. Oat3-/- females spent significantly less time immobile compared to their male 
counterparts at ages 3, 12, 15 and 18 mo of age.   Nonetheless, the decreased immobility 
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observed in our OAT knockout animals in the TST is comparable to published observations in 
the DAT, SERT, and norepinephrine transporter (NET) knockout mice, providing further 
evidence for involvement of OAT transporters in behaviors known to be regulated by 
monoaminergic neurotransmission (Xu et al., 2000; Holmes et al., 2002; Perona et al., 2008). 
 
 
Mean brain concentrations of DA and major metabolites, DOPAC and HVA, were 
significantly lower in aged (12, 15 and 18 mo) Oat1 and Oat3 deficient mice compared to aged 
matched WT levels. Interestingly, this decrease in DA did not cause any alterations in 
locomotion (i.e. hypolocomotion) as evident from the equivalent total distance traveled and total 
time mobile between all three strains in the OFA paradigm, as one would expect based on 
previous reports (Haenisch and Bonisch, 2011). It is possible that this alteration in DA 
concentration was not severe enough to elicit any phenotypical response in locomotor behavior 
or that the paradigm does not have adequate sensitivity to detect the degree of change. 
Conversely, mean tissue levels of 5-HT were found to be significantly lower in aged WT mice, 
but remained relatively unchanged in OAT knockout mice across age providing a possible 
correlative neurochemical change that could partly explain observed alteration in burying 
behavior in the Oat1-/- and Oat3-/- knockout mice . However, changes in tryptophan metabolic 
pathway enzyme levels may also occur and this remains to be explored. 
 
 
Because tryptophan has two metabolic pathways, the serotonergic pathway leading to 
production of 5-HT and 5-HIAA, and the kynurenine pathway leading to the production of 
uremic toxins (i.e. QA, NA, and XA) reportedly associated with inflammatory and non- 
inflammatory neurological diseases (i.e. schizophrenia) (Heyes et al., 1992; Erhardt et al., 2009; 
Olsson et al., 2012).  In addition, given that these metabolites have been shown to interact in 
87  
vitro with Oat1 and Oat3 transporters, it was of interest to investigate the possible impact of 
OAT deletion on concentrations of these metabolites in brain tissue. However, based on our 
findings, it appears that transporter deletion did not significant impact concentrations of these 
kynurenine metabolites. 
 
 
This study provides the first evidence indicating that Oat1-/- and Oat3-/- mice may serve 
as useful tools to further delineate the mechanisms underlying CNS control of monoamine 
homeostasis and suggesting a potential role for these transporter proteins in neurobehavioral 
disorders such as anxiety and depression. Alterations in the glutamatergic neurotransmission 
system have recently been shown to play a clinical role in compulsivity (Chakrabarty et al., 
2005; Egashira et al., 2008). Thus future studies aimed to study the effects of Oat1 and Oat3 
deletion on this system are needed as well. In addition, it would be of interest to investigate if 
pharmacologic antagonism of the Oat1 and Oat3 transporters produces similar behavioral and 
neurochemical effects as are observed in the OAT knockout models and reported consequences 
following administration of current pharmacotherapies used clinically for treatment of these 
affective disorders (i.e. selective serotonin reuptake inhibitors, serotonin/norepinephrine uptake 
inhibitors (Borsini et al., 2002; Cryan et al., 2005; Li et al., 2006; Castagne et al., 2011). 
However, comparisons of pharmacological antagonism of Oat1 and Oat3 vs. genetic deletion 
should be conservative as differences in behavioral phenotypes may be reflective of deletion 
during development. 
 
 
Further, it is also of interest to study the effects of Oat1 and Oat3 deletion on other 
factors shown to be involved in maintaining the CNS environment. As mentioned previously, 
one aspect of CNS regulation of monoaminergic neurotransmission involves pathways targeted 
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toward the efficient removal of released neurotransmitters (NTs), so-called uptake 1 and uptake 
2 transport systems. Neuronal uptake 1 is comprised of the well-studied DAT, SERT, and NET 
systems, which function to ensure rapid reuptake of released NTs by the pre-synaptic neuron. 
Additionally, members of the organic cation/anion/zwitterion transporter family (SLC22) have 
been suggested as the second, non-neuronal low affinity, high capacity transport system, uptake 
2, which functions to clear NTs and their degradative metabolites from the synaptic terminal 
region. Recent studies have found that NET knockout mice exhibited upregulation of the other 
reuptake transporters, DAT and SERT, in the brain indicating a compensatory change in the 
within the uptake 1 system as a result of loss of NET during development (Solich et al., 2011). 
Similarly, SERT KO mice demonstrated upregulated organic cation transporter 3 levels, 
providing evidence of compensatory changes in SLC22 transporters (proposed uptake 2 
mechanism) in response to loss of one of the uptake-1 transporters during development (Schmitt 
et al., 2003; Baganz et al., 2008). Lastly, as discussed above, many factors can influence 
clearance of neurotransmitters and relevant metabolites, including enzymatic breakdown. It was 
recently reported that DAT knockout mice exhibited down-regulated tyrosine hydroxylase, the 
enzyme responsible for metabolism of L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA), 
the precursor for DA and subsequently NE (Haenisch and Bonisch, 2011). In contrast, Daws et 
al found that SERT knockout mice exhibited no change in the levels of monoamine oxidase 
enzymes, MAO-A and MAO-B, responsible for catalyzing the oxidation of monoamine NTs to 
their acidic metabolites (Daws, 2009). Nonetheless, enzyme levels are still a potential factor 
that should later be investigated in this knockout model. In conclusion, behavioral and 
neurochemical analyses in OAT knockout mice revealed alterations in both anxiety-like and 
depressive-like   behaviors   with   correlative   changes   in   clearance   of   monoaminergic 
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neurotransmitters and metabolites. Additional work is required to further understand how 
genetic deletion of these transporters produces decreased susceptibility to anxiogenic and 
depressive phenotypes. 
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CHAPTER 5 
 
 
 
DETERMINATION OF L-GLUTAMIC ACID AND γ-AMINOBUTYRIC ACID IN 
MOUSE BRAIN TISSUE UTILIZING GC-MS/MS 
 
 
Drawn from manuscript submitted to Journal of Chromatography B, 2014. 
 
 
 
 
5.A. INTRODUCTION 
 
L-Glutamic acid (GA; MW=147.13 g/mol) and γ-aminobutyric acid (GABA; 
MW=103.12 g/mol) are neurotransmitters found in the brains of mammals. GABA is 
synthesized from GA by glutamate decarboxylase (Figure 5.1), yet the functions of these two 
neurotransmitters have opposing effects. GA is considered a major excitatory neurotransmitter 
in the central nervous system (CNS), while GABA is considered a major inhibitory 
neurotransmitter. Quantitation of these two neurotransmitters is important to the field of 
neuropharmacology, as they have been associated with learning and memory, the sleep cycle, 
and in clinical conditions including schizophrenia, Alzheimer’s disease, Parkinson’s disease, 
depression, anxiety, and obsessive-compulsive disorder (Bjarkam et al., 2001; Reinoso-Suarez 
et al., 2001; Das, 2003; Lewis et al., 2005; Yang and Shen, 2005; Bhagwagar et al., 2007; 
Gronli et al., 2007; Egashira et al., 2008; Schaeffer and Gattaz, 2008). 
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Figure 5.1. Structures of L-Glutamic Acid and γ-Aminobutyric Acid. 
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High performance liquid chromatography with electrochemical detection (HPLC-ECD) 
techniques have previously been used to study amino acid concentrations in the brain (Canevari 
et al., 1992; Murai et al., 1992; Boyd et al., 2000; Monge-Acuna and Fornaguera-Trias, 2009). 
Since the amino acids are not naturally electroactive, these methods typically require a 
derivatization step (usually using o-phthalaldehyde (OPA) in the presence of a thiol (e.g. β- 
mercaptoethanol) or a sulfite group). However, despite the sensitivity that can be achieved 
using HPLC-ECD, the electroactive derivatives are often unstable, and it has been reported that 
resolution may be problematic due to unknown peaks of biological origin that elute closely to 
GABA (Rowley et al., 1995; Clarke et al., 2007; Buck et al., 2009). 
In addition, there have been several publications using liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) for the analysis of GA and GABA in biological samples 
(Piraud et al., 2003; Song et al., 2005; Eckstein et al., 2008). However, to our knowledge, there 
are no currently published methods utilizing gas chromatography-tandem mass spectrometry 
(GC-MS/MS) offering quantitation of both GA and GABA in brain tissue. In this article, we 
describe a rapid and selective GC-MS/MS method for the detection and quantitation of GA and 
GABA in mouse brain homogenate. Stable isotopes of each compound were used as internal 
standards. The use of MethElute™ reagent (as described in (Farthing et al.)) rapidly derivatized 
GA and GABA and their isotopologues in the heated GC injection port, which required less than 
20 sec for completion and utilization of the low thermal mass (LTM) technology provided high 
resolution and fast chromatography. The method demonstrated excellent linearity from 0.5 to 
100 μg/mL, with limits of detections of 100 ng/mL and 250 ng/mL for GA and GABA, 
respectively.  The method was successfully used to assess the effects of deletion of the organic 
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anion transporter 1 (Oat1) and Oat3 in the mouse model on brain tissue concentrations of 
glutamate and GABA. 
 
 
5.B. EXPERIMENTAL 
 
5.B.1. Chemicals, Reagents, and Gases 
 
 
Standard material of L-Glutamic acid and γ-aminobutyric acid were purchased from 
Sigma Aldrich (St. Louis, MO). The 13C5-L-Glutamic acid (M+5 stable isotope, purity 99%) 
and U-13C4-4-aminobutyric acid (M+4 stable isotope, purity 98%) internal standards were 
purchased from Cambridge Isotopes (Andover, MA). 
MethElute™ derivatization reagent (0.2 M trimethylanilinium hydroxide in methanol, 
pH ≥ 10) was purchased from Thermo Scientific (Waltham, MA). Methanol (MeOH) (HPLC 
grade, 99.9% purity) was purchased from Acros Organics (Fair Lawn, NJ). Ultrapure deionized 
water (18 Ωohm-cm) was prepared daily using a Milli-Q Integral Water Purification system 
from EMD Millipore (Billerica, MA). 
Gases used for GC-MS/MS analyses were helium (grade 5.5 purity), nitrogen (ultra high 
purity), isobutane (Matheson 99.99% purity) and methane (research grade purity) and were all 
purchased from Roberts Oxygen Company (Rockville, MD). Gas purifiers used to remove 
hydrocarbons and moisture from the gases were purchased from Agilent Technologies (Santa 
Clara, CA). 
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5.B.2. Equipment and Software 
 
The Agilent 7890 GC, LTM series II fast GC module, 7000A GC-MS triple quadrupole, 
and 7693 autosampler were purchased from Agilent Technologies (Santa Clara, CA). The 
Agilent MassHunter software was used for GC-MS/MS data collection and processing including 
GC-MS/MS Acquisition (version B.05.02.1032), Qualitative Analysis (version B.04.00), and 
Quantitative Analysis (version B.05.00) 
An Eppendorf Model 5417R centrifuge was used to centrifuge down any particulate in 
the tissue homogenate prior to the derivatization step (Hauppauge, NY). The Savant DNA110 
SpeedVac® used for evaporating and concentrating samples was purchased from Thermo Fisher 
Scientific (Waltham, MA). 
 
 
 
5.B.3. GC-MS/MS Instrument Conditions 
 
The final GC and MS instrumental parameters used for sample analysis are listed in 
Table 5.1 and Table 5.2, respectively. 
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Table 5.1. Agilent 7890A GC and Autosampler Parameters 
 
GC Inlet  
Mode Pulsed Splitless 
Temperature (°C) 235 
Total Flow (mL/min Helium) 54 
Septum Purge Flow (mL/min Helium) 3 
Injection Pulse Pressure (psi until 1 min) 25 
Purge flow to split vent (mL/min Helium at 1.1 min) 50 
Gas saver (mL/min Helium after 3 min) 15 
  
GC Program  
Initial GC Oven Temperature (°C) 30 
Initial Oven Hold Time (min) 1 
Rate (°C/min) 75 
Final GC Oven Temperature (°C) 300 
Final Over Hold Time (min) 1.4 
Run Time (min) 6 
Equilibration Time (min) 0.1 
GC Transfer Line (°C) 300 
Oven Max Temperature (°C) 340 
  
GC Column  
LTM Column DB-5ms, 15m x 250μm x 0.25μm 
Head Pressure (psi) 2.14 
Flow (mL/min Helium) 1 
Average Velocity (cm/sec) 47 
Holdup Time (min) 0.5 
  
GC Autosampler  
Syringe Size (μL) 10 
Injection Volume (μL) 1 
Post Washes A 3 with ethanol 
Post Washes B 3 with acetone 
Samples Washes 1 
Sample Wash Volume (μL) 4 
Samples Pumps 3 
Viscosity Delay (sec) 3 
Air Gap (μL) 0.2 
  
GC Autosampler Barcode Mixer  
Mixer Enabled 
Mixer Cycle 1 
Mixer Time (sec) 10 
Mixer Speed (rpm) 2,000 
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Table 5.2. Agilent 7000A MS Parameters 
 
Helium Quench Gas (mL/min) 2.25 
Nitrogen Collision Gas (mL/min) 1.5 
Isobutane Reagent Gas (mL/min) 2 
Ion Source Temp (°C) 350 
Quad 1 Temperature (°C) 150 
Quad 3 Temperature (°C) 150 
Ion Source Chemical Ionization (CI) 
Mode Positive Ion (PCI) 
Electron Energy Mode Use tune settings 
Solvent Delay (min) 1.0 
Run Time (min) 6.0 
Time Filter Enabled  
Peak Width 0.7 
MS1 Resolution Unit 
MS2 Resolution Unit 
Dwell Time (msec) 50 
Scan Rate (cycles/sec) 5 
Collision Energy-GA (V) 15 
Collision Energy-GABA (V) 20 
Electron Multiplier (V) 1600 
Delta EMV (V) 400 
HED (kV) -10 
  
Instrument Tuning (Mass Calibration)  
Tune MS weekly or as necessary  
  
MRM Transitions  
GA derivative (precursor ion/product ion) m/z 204/144 
d5-GA derivative (precursor ion/product ion) m/z 209/148 
GABA derivative (precursor ion/product ion) m/z 146/101 
D4-GABA derivative (precursor ion/product ion) m/z 150/105 
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5.B.4. GC-MS/MS Calibration Standards and Internal Standards 
 
 
Stock standard solutions of GA and GABA (1 mg/mL) were prepared in deionized water 
and deionized water:MeOH (50:50 v/v), respectively, and stored at -20°C until analysis. GA 
was found to be insoluble in aqueous solutions with varying percentages of organic modifiers 
(e.g. 70/30 v/v; 80/20 v/v; 90/10 v/v deionized water:MeOH). Working calibration standards 
(0.5, 2.5, 5, 10, 25, 50 and 100 μg/mL) were prepared containing GA and GABA, and their 
stable isotopes GA M+5 and GABA M+4 (internal standards) and stored at -20°C until analysis. 
The calibration standards were prepared by adding 50 μL of standard to the microvial insert 
(Agilent, Santa Clara, CA) and evaporated to dryness (~45 min at 45°C) using the Savant DNA 
SpeedVAC. For reconstitution, 50 μL of the MethElute™ derivatizing reagent was added to the 
autosampler microvial containing the sample residue, capped, and vortexed for 15 sec prior to 
placement on the autosampler. The internal standard (I.S.) working solution was prepared by 
appropriate dilutions of the stock solution with deionized water. The I.S. working solution 
contained 10 μg/mL GA M+5 and GABA M+4. 
 
 
 
5.B.5. Brain Sample Preparation 
 
 
Tissue samples were homogenized prior to analysis by GC-MS/MS. For sample 
analysis, brain homogenates were thawed, vortexed for 30 sec, and centrifuged at 2500 rpm for 
5 min. Following centrifugation, 50 μL of brain homogenate and 50 μL of internal standard 
were added to the microvial insert (Agilent, Santa Clara, CA) and evaporated to dryness (~45 
min at 45°C) using the Savant DNA SpeedVAC.  For reconstitution, 50 μL of the MethElute™ 
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derivatizing reagent was added to the autosampler microvial containing the sample residue, 
capped, and vortexed for 15 sec prior to placement on the autosampler. 
 
 
 
5.B.6. Method Validation 
 
 
The method was validated in terms of linearity, sensitivity, selectivity, intra- and inter- 
day accuracy and precision, and stability. The linearity was evaluated using a weighted (1/x) 
quadratic analysis of calibration standards from 0.5-100 μg/mL (n = 3). The sensitivity was 
established by determining the lower limit of quantitation (LLOQ) and the limit of detection 
(LOD) for each component. The combined inter-day and intra-day accuracy and precision of 
the method was evaluated using calibrators from the standard curves (n = 3). Instrument 
injector precision and derivatization reproducibility were evaluated by using replicate injections 
of the 25 μg/mL calibration standard (n=6). The stability of GA and GABA were evaluated 
using the mid calibration standard (10 μg/mL) at 0, 3, 5, 7 and 18 hours at room temperature on 
the autosampler. Freeze/thaw stability was evaluated using wild-type control brains prepared 
and injected following one freeze thaw cycle. 
 
 
 
5.B.7. Computations 
 
 
Component computations were performed using MS multiple reaction monitoring 
(MRM) mode and peak height response with MassHunter quantitation software (Agilent 
Technologies, Santa Clara, CA). The seven point calibration curve was a plot of the standard 
concentrations versus the ratio of the peak height of the component and its internal standard. 
Calibration curves were constructed for each analytical run. 
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5.C. RESULTS AND DISCUSSION 
 
5.C.1. GC-MS/MS Method Development and Optimization 
 
 
DB-17ms and DB-5ms columns were evaluated for this method. The DB-5ms column 
provided better peak shape of GABA, as compared to the moderately polar DB-17ms column, 
most likely due to the non-polar nature of the GABA derivative. 
MS/MS optimizations were performed for both GA and GABA. Samples were injected 
in chemical ionization mode (positive ion mode) with data collected at unit mass resolution in 
MRM mode. The precursor ions were isolated in the first quadruple and further fragmented 
with different collision energies (15, 20 V) with optimal collision energies of 15V for GA and 
20V for GABA. The third quadruple then sorts these fragments for detection. The main 
characteristic ions of GA and GABA produced major product ions at m/z 144 and m/z 101, 
respectively. Therefore, the precursor/product ion pairs of m/z 204 m/z 144 and m/z 146  
m/z 101 were chosen as MRM transitions of GA and GABA, respectively. Figure 5.2 shows 
chromatogram overlays representing MRM of the 25 µg/mL standard and a representative brain 
sample. 
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Figure 5.2. Chromatographic overlays representing typical multiple reaction monitoring of 
the (A) 25 µg/mL standard and (B) a representative brain sample. 
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The method can be made more sensitive by altering the sample preparation. For the 
current purpose, a 1:1 ratio (50μL sample: reconstituted in 50 μL derivatizing agent) was used 
for reconstitution; however, by changing the ratio (v/v) (e.g. 150 μL sample: reconstituted in 25 
μL derivatizing agent) sensitivity was increased 5 fold (data not shown). 
 
 
 
5.C.2. GC-MS/MS Method Validation 
 
 
The calibration curve (peak height ratio of analyte to internal standard vs. concentration) 
for both GA and GABA was evaluated using a 1/x weighted quadratic analysis and was linear 
over the range of 0.5-100 μg/mL (n = 3) with a correlation coefficient value ≥ 0.998. A typical 
calibration plot for each component is shown in Figure 5.3. The lower limit of quantitation 
(LLOQ) for both components was defined as the lowest calibration standard (0.5 μg/ml), which 
can be accurately and precisely determined with less than 20% total error. The limit  of 
detection (LOD) was determined by conducting dilutions of each component’s lowest 
calibration standard until the MS signal approached background noise. The LOD was 
determined to be 100 ng/mL and 250 ng/mL for GA and GABA derivatives, respectively 
(Figure 5.4). 
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Figure 5.3. A typical calibration curve (peak height ratio of analyte to internal standard vs. 
concentration) for (A) GA and (B) GABA using a 1/x weighted quadratic analysis. The 
standards used for calibration were prepared at concentrations of 0.5, 2.5, 5, 10, 25, 50 and 
100 μg/mL. 
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Figure 5.4. Chromatogram overlays representing multiple reaction monitoring of the LOD 
for GA (panel A bottom; 100 ng/mL at RT = 3.16 min) and GABA (panel B bottom; 250 
ng/mL at RT = 2.49 min) relative to MethElute™ derivatizing agent only (top panels). 
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The combined intra-day and inter-day accuracy and precision were evaluated using 
standard curves (Table 5.3). Accuracy (% error) was determined by the difference between 
((measured concentration-nominal concentration)/(nominal concentration))*100. Precision 
(%CV) was determined by dividing the standard deviation by the mean (SD/mean)*100. Intra- 
day instrument injector precision and online heated GC inlet derivatization reproducibility were 
evaluated by using repetitive injections of the 25 μg/mL calibration standard (Table 5.3). The 
instrument injector precision was less than 7% C.V. and online heated derivatization procedure 
was very reproducible. 
  
Table 5.3. Intra-day and Inter-day accuracy and precisions of GA and GABA calibration standards. 
 
 
Combined Intra-Day and Inter-Day Accuracy and Precision 
 
 GA     GABA  
Conc. 
 
0.5 
Measured 
Conc. 
0.5 
SD 
 
0.02 
% Error 
 
-3.3 
% CV 
 
3.2 
Conc. 
 
0.5 
Measured 
Conc. 
0.5 
SD 
 
0.02 
% Error 
 
0.0 
% CV 
 
3.5 
2.5 2.5 0.18 -1.6 7.4 2.5 2.5 0.03 1.2 1.2 
5 4.8 0.22 -3.3 4.6 5 4.9 0.03 -1.8 0.7 
10 10.8 0.21 7.8 2.0 10 10.4 0.33 4.2 3.1 
25 25.9 1.07 3.9 4.1 25 23.7 0.20 -5.2 0.8 
50 47.4 1.51 -5.2 3.2 50 51.3 0.36 2.7 0.7 
100 101.1 0.59 1.1 0.6 100 97.9 2.69 -2.1 2.7 
 
Instrument Precision and Derivatization Reproducibility 
  
GA 
    
GABA 
  
Conc. Measured 
Conc. 
SD % Error % CV Conc. Measured 
Conc. 
SD % Error % CV 
25 25.4 1.59 1.4 6.3 25 24.1 0.3 -3.7 1.4 
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A stability study was performed to evaluate the component’s stability in the 
MethElute™ derivatizing reagent. The stability of GA and GABA were evaluated using the 
mid calibration standard (10 μg/mL) at 3, 5, 7 and 18 hours at ambient room temperature on the 
autosampler, as compared to freshly prepared and analyzed 10 μg/mL calibration standard. The 
results of the stability study indicate that GA and GABA are stable in the MethElute™ 
derivatizing agent for at least 7 hrs (typical run length), but are not stable at 18 hrs (< 10% 
degradation of GA, and ~30-40% degradation of GABA). Freeze/thaw stability was also 
evaluated using wild-type control brains (n =4) prepared and injected following one freeze thaw 
cycle. Both components were stable through one freeze thaw cycle. 
 
 
 
5.C.3. Method Application 
 
 
The validated method has successfully been applied for the quantitative detection of GA 
and GABA in mouse brain tissue of organic anion transporter (OAT) knockout mice. Mice 
(C57Bl/6J background) of three genotypes: wild-type (WT), Oat1 transporter knockout (Oat1-/-), 
and Oat3-/- at two ages (3 mo vs. 18 mo of age) were used for initial assessment (n = 4 in each 
group). It was hypothesized based on our previous behavioral assessments (specifically, in the 
marble burying procedure, a model of compulsive-like behavior) that the GA/GABA system 
may be altered over age from the loss of OAT transporter function in the brain. Brain tissue 
samples were previously collected following completion of the behavioral assessments, and 
homogenates were aliquoted and stored at -80°C until analysis. The concentrations of GA and 
GABA in brain homogenates for each group are shown in Figure 5.5 (panel A). As can be seen 
from Figure 5.5 (panel B), GABA remained relatively unchanged across and within genotype. 
GA concentrations also remained unchanged within all three genotypes; however, a trend was 
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observed  with  lower  concentrations  of  GA  in  both  of  the  aged  OAT  knockout  genotypes 
compared to age matched WT mice. 
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Figure 5.5. The concentrations of GA and GABA in brain homogenates for each group are 
shown. As can be seen in panel B, GABA concentrations remained relatively unchanged 
across and within genotype. GA concentrations also remained unchanged within all three 
genotypes (panel A); however, a trend was observed with lower concentrations of GA in 
both of the aged (18 mo) OAT knockout genotypes, as compared to age matched WT mice. 
There were n = 4 mice in each of the groups (e.g. WT 3 mo, WT 18 mo, Oat1-/- 3 mo, etc.). 
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5.D. CONCLUSIONS 
 
We developed a rapid and selective GC-MS/MS method for the detection and 
quantitation of GA and GABA in mouse brain homogenate. The method employed an online 
hot inlet gas phase derivatization technique, which required less than 20 sec for completion and 
fast chromatography by utilization of the LTM technology.  The method demonstrated excellent 
linearity from 0.5 to 100 μg/mL, with limits of detections of 100 ng/mL and 250 ng/mL for GA 
and GABA, respectively.  The method was used to investigate the role of organic anion 
transporter deletion on concentrations of GA and GABA in the mouse brain. 
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CHAPTER 6 
 
 
 
OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
According to the World Health Organization, mental disorders represent the leading 
cause of disability in the US generating ~58 billion dollars in medical costs annually. 
Additionally, among the US population, ~40 million adults suffer from an anxiety disorder and 
~14 million suffer from a major depressive disorder. The association between the persistence of 
these neurobehavioral conditions and CNS levels of biogenic amines and metabolites has been 
studied for half a century. Further, a large number of drugs interfering with 
neurotransmission/metabolism are used clinically for treatment of these disorders. Recently, 
some members of the SLC superfamily, the SLC22 transporter family, which includes Oat1 and 
Oat3, were found to be expressed and functional on the apical membrane of the choroid plexus, 
a component of the blood cerebrospinal fluid barrier. The cells of this epithelium form tight 
junctions, which slows penetration of solutes into the brain and limits passive efflux of 
endogenous solutes from the brain. Therefore, Oat1 and Oat3 are poised to play an active role in 
the removal of NTs and metabolites from the CSF. Thus, this dissertation intended to provide an 
increased understanding of the physiological roles of OATs in regulating CNS neurotransmitter 
and relevant metabolite concentrations and connect their activity to complex behaviors known to 
be associated with alterations in neurotransmission. 
 
In Chapter 3, a simple HPLC-UV/ECD method was developed and validated for the 
simultaneous  determination  of  various  monoamine  neurotransmitters  (DA,  NE,  5-HT)  and 
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relevant metabolites (DOPAC, HVA, 5-HIAA, QA, NA, XA) in mouse brain tissue. This 
method introduced several advantages over previous methods in that it uses relatively 
inexpensive mobile phase constituents, requires minimal sample preparation and small injection 
volume, while preserving sufficient chromatographic separation of the 9 components of interest, 
simultaneously. This assay was developed to successfully determine concentrations of the NTs 
and metabolites at the whole brain level in WT, Oat1-/- and Oat3-/- mice. Metabolic product 
accumulation occurs over time; therefore, the neurochemical measures were examined at 
multiple time points (e.g. 3, 6, 9, 12, 15 and 18 mo) in both male and female mice to determine 
key milestones in the development of neurobehavioral abnormalities. This approach is 
consistent with the age- and gender-dependent development of different psychopathologies in 
humans. This design represents a novel methodology as relatively few studies provide a 
systematic evaluation of neurochemical and behavioral changes over time, particularly in aged 
animals. 
 
The preliminary studies in Oat1-/- and Oat3-/- mice presented in Chapter 4 of this 
dissertation provide the first behavioral data indicating that loss of function of Oat1 and Oat3 in 
the CP results in measurable behavioral consequences. Basal locomotor, anxiety-like and 
depressive-like behaviors in mice across genotype (WT, Oat1-/- and Oat3-/-) and across ages (3- 
18 mo) were evaluated using behavioral paradigms (OFA, LD, MB and TST). The OFA 
paradigm is considered a classical test of exploratory locomotor behavior that provides a 
measure of basal activity and, thus, is an essential component of behavioral phenotyping. In 
addition, patterns of activity within the field can be determined providing additional information 
about novel strains. In the current study, the total time spent mobile and the total distance 
traveled in the OFA paradigm were parameters used to measure basal motor activity across 
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genotype at any given age. We found that there were no significant differences in these 
measures across age for each of the genotypes and across genotype at any given age. Therefore, 
any alterations observed in anxiety-like or depressive-like behaviors in the additional paradigms 
are not simply reflective of genotype or aged-related differences in basal motor activity. 
Similarly, there were no significant differences in thigmotactic behavior observed when 
comparing the distance traveled in the center zone and time in the center zone as a percent of the 
total distance traveled and total time mobile in the field across strain by age, genotype, and 
gender. Finally, when we evaluated environmental neophobia by comparing total distance 
traveled and total time mobile in the field on Day 1 vs. Day 2, we found that there were no 
significant differences across age for each of the genotypes or across genotype at any given age 
in habituation patterns. 
 
Perhaps the most interesting finding in Chapter 4 was the behavioral consequence of Oat 
transporter deletion evident in the MB paradigm. Marble burying has been suggested as a 
model to measure anxiety-like behaviors, specifically compulsivity, and has been proposed as a 
possible model of obsessive compulsive disorder in rodents (Albelda and Joel 2012). In the 
current study, Oat1-/- and Oat3-/- mice nearly eliminated burying behavior at 15 and 18 mo of 
age. These findings may suggest decreased anxiety-like or compulsive-like behavior in the aged 
Oat deficient mice and suggest that these knockout mice may be useful as a model of anti- 
anxiety/compulsivity at older ages (i.e. 15 and 18 mo). Because results from the OFA did not 
detect any significant differences in the total time spent mobile or the total distance traveled in 
the field, the marble burying results do not simply reflect lower basal activity levels, but 
demonstrate true differences in burying behavior. The pattern of anxiolytic effect in our aged 
knockout mice is similar to what has been observed in the marble burying procedure for SERT 
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and DAT knockout mice, and when WT mice are administered therapeutic agents used 
clinically to treat such disorders (e.g. citalopram, fluoxetine) (Kobayashi et al., 2002a; Line et 
al., 2011; Pang et al., 2011; Fox et al., 2013) 
 
The TST paradigm measuring depressive-like behavior provided the first significant 
differences between Oat1-/- and Oat3-/- mice. When comparing the knockout strains to each 
other at each time point, the point where they significantly deviated from each other was at 3 mo 
of age, with Oat1-/- mice exhibiting significantly decreased immobility compared to Oat3-/- and 
WT mice at 3 mo. When comparing the knockout genotypes relative to WT at each time point, 
there were significant differences at varying ages with an overall trend of knockout mice 
spending less time immobile compared to WT. The Oat1-/- mice spent significantly less time 
immobile compared to WT at 3 and 9 mo of age, while the 6 mo Oat1-/- mice tended to also 
spent less time immobile than WT. Oat3-/- mice spent significantly less time immobile 
compared to age-matched WT at 6, 9 and 15 mo of age. Perhaps, the inconsistencies in this 
measure of depressive-like behavior can be partly explained by the first and only observed 
gender-specific variations. Oat3-/- females spent significantly less time immobile compared to 
their males counterparts at ages 3, 12, 15, and 18 mo of age. This was an important finding 
because it highlights the importance of not collapsing data across genders without evaluating 
each gender separately with appropriate sample sizes as most pharmacologic and behavioral 
studies are conducted at earlier ages (3 mo - 6 mo) and only using one gender. Interestingly, 
there were no gender-specific differences observed within the Oat1-/- strain. Nonetheless, this 
observation in our knockout mice of decreased immobility in the TST is comparable to 
published observations in the DAT, SERT, and norepinephrine transporter (NET) deficient mice 
providing further evidence for involvement of OAT transporters in behaviors known to be 
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regulated by monoaminergic neurotransmission (Xu et al., 2000; Holmes et al., 2002; Perona et 
al., 2008). 
 
Following completion of behavioral assessments, whole brain concentrations of 
monoamines and metabolites were determined using the developed HPLC-UV/ECD method 
described in Chapter 3. The biochemical data on brain NT levels presented in Chapter 4 of this 
dissertation represent the first correlative evidence that the hypothesis of OAT involvement in 
maintaining endogenous CNS levels of NTs and metabolites is correct. As discussed in Chapter 
3, tissue levels of DA in Oat1-/- and Oat3-/- mice at 12, 15 and 18 mo of age were significantly 
decreased compared to age matched WT. Similarly, concentrations of the DA metabolites, 
DOPAC and HVA were also significantly lower in aged Oat-/- mice (12, 15 and 18 mo) 
compared to age-matched WT mice. In contrast, NE concentrations in Oat1-/- and Oat3-/- mice at 
any given age were not significantly different compared to age matched WT; however, there 
was a trend for NE concentrations to decrease with age in all genotypes. Interestingly, mean 
tissue concentrations of 5-HT were significantly decreased in WT at 12, 15 and 18 mo of age 
compared to age matched Oat1-/- and Oat3-/- mice while there was no significant change in mean 
concentrations of 5-HIAA. Lastly, we found that there were no differences in the mean 
concentrations of the kynurenine metabolites, QA, NA, and XA, across genotype at 3, 12 and 18 
mo or within genotype across the specified ages. 
 
 
Based on our extreme findings with aged knockout mice nearly ceasing burying 
behavior in the MB procedure, which has been suggested in literature to be used as a model of 
compulsive-like behavior (Ichimaru et al., 1995; Thomas et al., 2009), and given that 
abnormalities  in  the  glutamate/γ-aminobutyric  acid  system  have  been  implicated  in  the 
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physiology of this disorder (Egashira et al., 2008), we hypothesized that GA and/or GABA 
concentrations may be altered over age from the loss of OAT transporter function in the CNS. 
In addition, in vitro studies have demonstrated that both of these amino acid NTs interact with 
OAT transporters (Mori et al., 2003). Therefore, based on this information, investigations of 
whole brain concentrations of GA and GABA were logical progressions. 
 
Lastly, as described in Chapter 5, a novel GC-MS/MS method was developed for 
quantitation of amino acid neurotransmitters, GA and GABA, in mouse brain tissue. There were 
no currently published methods utilizing GC-MS/MS offering quantitation of both GA and 
GABA in brain tissue. In this dissertation, we describe a rapid and selective GC-MS/MS which 
utilized stable isotopes of each compound as internal standards. The use of MethElute™ reagent 
rapidly derivatized GA and GABA and their stable isotopes in the heated GC injection port, 
which required less than 20 sec for completion and utilization of the low thermal mass (LTM) 
technology provided high resolution and fast chromatography. The method demonstrated 
excellent linearity from 0.5 to 100 μg/mL, with limits of detections of 100 ng/mL and 250 
ng/mL for GA and GABA, respectively. The developed method was successfully used for 
measurement of whole brain concentrations of GA and GABA in a small subset of WT, Oat1-/-, 
and Oat3-/- mice at 3 and 18 mo. Brain tissue samples were previously collected following 
completion of the behavioral assessments, and homogenates were aliquoted and stored at -80°C 
until analysis. The concentration of GABA remained relatively unchanged across and within 
genotype. GA concentrations also remained unchanged within all three genotypes; however, a 
trend was observed with lower concentrations of GA in both of the aged OAT knockout 
genotypes compared to age matched WT mice. 
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These studies have only scratched the surface in terms of our understanding of the 
endogenous physiological roles of these transporters in the CP. Our study provides the first 
evidence suggesting that the complex behavioral profiles observed in the Oat1-/- and Oat3-/- mice 
may serve as a tool to better understand the mechanisms underlying neurobehavioral disorders 
such as anxiety, compulsivity and depression. However, it should be noted that the CNS is a 
dynamic system that has many additional factors (i.e. other transporters, receptors, enzymes) 
responsible for maintaining concentration of endogenous substances (i.e. neurotransmitters and 
their metabolites) and thereby behaviors associated with their concentrations. Thus, immediate 
studies should include investigations of the impact of Oat1 deletion on the levels of Oat3 and 
vice versa. It would also be of interest to investigate if pharmacologic antagonism of Oat1 or 
Oat3 elicits similar behavioral and neurochemical consequences as observed in Oat-/- mice. 
Additionally, given our understanding of the overlapping specificities for NTs and their 
metabolites and overlapping tissue expression profiles of Oat1 and Oat3, it would be of interest 
to develop an Oat1/Oat3 double knockout mouse model to truly delineate the role of OAT’s, 
although this is a difficult challenge due to linkage of the genes and it remains unknown if a 
double knockout model would be embryonic lethal. Lastly, future studies exploring the 
redundancy in the CNS should also include investigations of the levels of other transporters 
known to be involved in neurotransmission (i.e. SLC6 transporters (DAT, NET, SERT) and 
OCTs (uptake 2)) as a response to delection of OAT transporters. Evidence of compensatory 
changes and the dynamic interplay between these two transporters families (SCL6 and SLC22) 
in knockout animals has already been reported with SERT knockout mice exhibiting increased 
levels of Oct3 (Schmitt et al., 2003; Baganz et al., 2008). Continuing our discussion of the 
dynamic nature of the CNS environment, other important investigations to be considered also 
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includes evaluating levels of metabolic enzymes (i.e. MAOs, TH, COMT) responsible for 
maintain homeostatic concentrations of neurotransmitters, and evaluating receptor levels (i.e. 
dopamine receptors and serotonin receptors) in these knockout models. 
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APPENDIX I 
 
COMPARISON OF BODY WEIGHT (G) BY GENOTYPE AND GENDER ACROSS 
AGE 
 
 
Body weight was collected for all animals used in the behavioral analyses described in 
Chapter 4.  As demonstrated in the graph below, males of all genotypes (solid lines) had higher 
body weights compared to their age matched female counterparts (dashed lines).  Despite this 
increase in body weight, mice remained similar in their overall baseline motor activity as 
indicated by the total time mobile and total distance travelled in the open field paragidm as 
discussed in Chapter 4. 
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APPENDIX II 
 
 
ASSESSMENT OF BLOOD PRESSURE BY GENOTYPE AND AGE 
 
 
 
 
 
Vallon et al reported in a 2008 article in the Journal of the American Society of 
Nephrology that Oat3-/- mice had 10-15% lower systolic, diastolic, and mean arterial blood 
pressure (MABP) compared to WT and Oat1-/- mice. Systolic blood pressure was measured 
using he tail-cuff method in awake mice, while MABP was measured in anesthetized mice via 
intra-arterial catheter.  Systolic and diastolic blood pressure was measured in a small subset of 
WT, Oat1-/-, and Oat3-/- mice (n = 4-6 in each group) using the tail-cuff method and correlated 
with the findings reported by Vallon et al.  As demonstrated in the graph below, Oat3-/- 
demonstrated decreased systolic and diastolic blood pressure compared to WT and Oat1-/- at 3 
mo of age.  Interestingly, we found that at 18 mo of age, both Oat1-/- and Oat3-/- mice 
demonstrated decreased systolic and diastolic pressure compared to WT mice at 18 mo. These 
results indicate the potential implication of these transporters in blood pressure regulation. 
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